document incorporate reference specify portion registrant definitive proxy statement file commission pursuant regulation connection annual meeting incorporate reference iii report base closing price share exclude share registrant common stock hold executive officer director stockholder ownership exceed common stock outstanding february exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrant february march registrant implement twoforone stock split form stock dividend share share amount period present restate reflect split iitem business forwardlooke statement risk factor report include forwardlooke statement particular statement expectation belief plan objective assumption future event performance contain incorporate reference report base forwardlooke statement current expectation future event believe expectation reasonable forwardlooke statement inherently subject risk uncertainty control actual result differ materially suggest forwardlooke statement reason include discuss report head risk factor give risk uncertainty caution place undue reliance forwardlooke statement forwardlooke statement include report date hereof undertake specifically decline obligation update statement publicly announce result revision statement reflect future event development overview gilead sciences inc independent biopharmaceutical company discover develop commercialize therapeutic advance care patient suffer lifethreatening disease worldwide market product focus research clinical program antiinfective include antiviral antifungal antibacterial headquarter foster city california marketing operation country include united states australia european country endeavor grow exist portfolio product proprietary clinical development program internal discovery program active product acquisition inlicense strategy internal discovery activity include identification new molecular target target screen medicinal chemistry expertise liposomal drug delivery technology use develop drug safe easy patient tolerate effective incorporate delaware june product currently market country worldwide viread approve sale use combination antiretroviral agent treatment hiv infection european union use combination antiretroviral agent treatment hiv infection patient experience early virological failure ambisome approve sale country treatment lifethreatening fungal infection country prevention infection market ambisome major country europe copromote ambisome fujisawa healthcare inc tamiflu sell corporate partner hoffmannla roche country treatment influenza approve prevention influenza vistide approve sale country treatment cmv retinitis aid patient daunoxome approve sale country treatment aidsrelate kaposi sarcoma sale force promote viread ambisome vistide daunoxome international sale force europe australia promote viread ambisome daunoxome corporate partner distributor promote ambisome vistide daunoxome country study adefovir dipivoxil ongoing phase iii trial treatment infection hepatitis virus hbv file regulatory approval europe base result date believe adefovir dipivoxil potential address limitation current hbv therapy notably drug resistance associate longterm therapy november announce enter agreement osi pharmaceuticals inc osi value million cash stock agree sell oncology asset osi transaction complete december record gain million transaction allow focus continue strengthen core expertise infectious disease transaction sell osi pipeline clinical candidate oncology relate intellectual property boulder colorado operation include clinical research drug development operation infrastructure facility completion transaction osi pay million cash share osi common stock osi pay additional million cash combination cash osi common stock achievement certain milestone osi relate development advanced oncology product candidate sell transaction manufacturing agreement active ingredient supply osi produce liposomal product include sale manufacturing facility san dimas california market product product develop commercially available include viread drug treat hiv infection ambisome drug treating prevent lifethreatening fungal infection tamiflu drug treating prevent influenza vistide drug treat cytomegalovirus cmv retinitis aid patient daunoxome drug treat aidsrelated kaposi sarcomahow product sell indication approve vary product country region sell earn revenue approximately million sale royalty product sale ambisome generate aggregate product sale royalty revenue approximately million total revenue earn revenue sale royalty product million million million outside earn revenue sale royalty product million million million begin recognize revenue commercial sale viread november expect revenue earn sale viread comprise increase percentage total revenue decrease percentage total revenue sale ambisome predict certainty future revenue ambisome viread viread viread formulation nucleotide analogue reverse transcriptase inhibitor tenofovir dose pill day combination therapy treat hiv infection adult viread approve sale use combination antiretroviral agent treatment hiv infection sale european union use combination antiretroviral agent treatment hiv infection patient experience early virological failure sell viread sale force major european country european sale force marketing sale september february respectively announce week week effectiveness safety result study week pivotal phase iii clinical trial evaluate viread component combination therapy treatmentexperience patient site europe australia design study provide conclusive data safety effectiveness viread study patient randomly divide group group patient viread add exist therapy week twothird enrol patient group patient give placebo addition exist therapy week onethird enrol patient patient give viread addition exist therapy second week result demonstrate follow week week treatment viread reduce patient serum hiv dna measure hiv week average approximately logcopiesml meet primary endpoint trial compare reduction approximately log copiesml patient receive placebo week approximately log copiesml viread suppress hiv viral load copiesml week approximately patient compare patient receive placebo week patient viread increase patient cell count week week patient receive placebo cell count decrease week increase cell count important indication hiv drug improve patient immune system rate discontinuation use week equivalent patient viread patient placebo viread cause significant increase effect relative placebo weeks safety profile viread week similar week percent patient receive viread develop resistance viread week additionally viread treatment week significantly reduce development mutation associate class antiretroviral agent know protease inhibitor compare placebo group september present result week phase dose range clinical trial tenofovir treatmentexperience patient study patient receive dose tenofovir placebo addition exist combination therapy week patient receive placebo switch dose trial show patient population follow week treatment high dose tenofovir associate low level serum hiv dna compare placebo week high dose tenofovir associate low level serum hiv dna compare baseline measurement point great reduction observe group study show week dose tenofovir result increase adverse event compare low dose tenofovir phase iii result study combine complete phase result support belief viread important treatment option difficult treat treatmentexperience patient datum study week datum study datum clinical trial form basis marketing application food drug administration fda approve october european union application approve february continue evaluate viread treat patient prior hiv therapy january complete enrollment patient study phase iii clinical trial compare safety effectiveness treatment patient prior hiv therapy viread combination lamivudine efavirenz safety effectiveness treatment stavudine lamivudine efavirenz study provide additional information viread treat patient population successful form basis supplemental marketing application european union use major challenge treat hivinfecte patient drug resistance exist therapy treat hiv infection aid rely similar drug process patient develop resistance drug develop resistance drug class believe viread approve regulatory authority important drug treatmentexperience patient available datum show patient develop rapid resistance viread viread effective treat patient develop resistance therapy certain resistance datum obtain completion phase iii clinical trial similar resistance characteristic week week datum study datum obtain limited phase clinical trialsanother major concern hiv treatment convenience dose combination therapie positive impact health hiv infect patient require patient numerous different drug drug require multiple dose day time restriction result inconvenience patient contribute patient miss dose adhere therapy viread approve administer oncedaily oral pill schedule appeal hivinfecte patient physician low discontinuation rate observe viread support belief december discontinue develop adefovir dipivoxil treat hivinfecte patient decision follow recommendation fda advisory panel approve dose adefovir dipivoxil treat hiv infection primarily concern kidney toxicity develop late trial desire additional evidence treatment benefit tenofovir structure activity similar adefovir dipivoxil viread associate kidney toxicity show superior treatment benefit clinical trial certain kidney toxicity issue occur later stage phase iii clinical trial adefovir dipivoxil hiv arise viread viread face substantial competition number drug treat hiv infection aid currently sell advanced stage clinical development include product currently sell major pharmaceutical company significant competitor hivaid market glaxosmithkline bristolmyers squibb hoffmannla roche pfizer merck boehringeringelheim abbott laboratories competition exclusive worldwide license patent right relate technology viread institute organic chemistry biochemistry academy sciences czech republic rega stichting vzw iocbrega obligate pay net revenue sale viread iocbrega european union country product approve patent protection collaborative relationship iocbrega ambisome ambisome liposomal formulation amphotericin amphotericin powerful antifungal agent know ability attack kill broad variety lifethreatening fungal infection effect include kidney toxicity patient likely suffer fungal infection patient weaken immune system include transplant patient patient infect hiv cancer patient undergo chemotherapy study deliver amphotericin proprietary liposomal formulation ambisome reduce rate severity kidney toxicity injection relate reaction allow patient receive high effective dose amphotericin ambisome approve sale country include european union rest europe australia canada country middle east latin america asia ambisome primarily treat patient know lifethreatening fungal infection country ambisome approve include authorize promote ambisome line treatment patient remain country ambisome approve use indication conventional amphotericin therapy fail conventional amphotericin second line therapy addition ambisome approve country line therapy patient certain symptom presume fungal infection country ambisome approve line treatment acute cryptococcal meningitis aids patient addition ambisome approve treatment prevent fungal infection liver transplant patient country additional type transplant patient russia ambisome approve treat parasitic infection call visceral leishmaniasis country copromote ambisome fujisawa healthcare domestic sale force agreement fujisawa entitle percentage revenue generate sale provide fujisawa purchase ambisome manufacturing cost collaborative relationship fujisawa major european country australia sell ambisome international sale force certain country sell ambisome independent distributor marketing sale corporate partner sumitomo study ambisome clinical trial japan drug approve marketing sumitomo exclusive right sell ambisome japan receive percentage revenue receive sale collaborative relationshipssumitomo revenue ambisome europe expect case foreseeable future major european country sell ambisome currency country revenue dollar decrease value currency decrease relative value dollar ambisome current expect competitor conventional amphotericin market ambisome approve line therapy conventional amphotericin bristol myers squibb company numerous generic manufacturer country ambisome prescribed conventional amphotericin therapy fail caspofungin product develop merck receive marketing approval january european union marketing approval october voriconazole develop pfizer inc receive marketing approval european union march fda deem pfizer new drug application nda voriconazole approvable lipidbase amphotericin product approve europe include abelcet sell elan corporation amphotec sell intermune pharmaceutical inc product compete ambisome primary secondary therapy generally offer price ambisome price competition tamiflu tamiflu oral pill treatment prevention influenza tamiflu class prescription drug call neuraminidase inhibitor act disable common strain flu virus prevent virus spread patient tamiflu originally approve fda october treatment uncomplicated influenza adult patient november approve fda prevention influenza adult adolescent year old december tamiflu approve japan treatment influenza adult treatment child young year old march application european union market tamiflu treatment prevention influenza recommend approval ascientific advisory committee responsible agency approve treatment influenza tamiflu show reduce duration flu adult average day reduce severity flu symptom incidence secondary infection take approve prevention influenza study show tamiflu effective prevent development flu common effect associate tamiflu mild nausea vomit hoffmannla roche corporate partner develop tamiflu exclusive right sell tamiflu begin sell tamiflu november hoffmannla roche submit marketing authorisation application european union seek tamiflu approve centralized procedure european union application withdraw hoffmannla roche enable hoffmannla roche submit additional data application refile hoffmannla roche february january hoffmannla roche announce production problem liquid suspension form tamiflu approve treatment child young year old available expect available flu season production issue affect availability tablet form tamiflu adult adolescent year old expect current production issue material effect earning receive percentage net revenue hoffmannla roche generate sale tamiflu collaborative relationshipshoffmannla roche product available treat flu time show effective safe neuraminidase inhibitor relenza antiflu drug sell glaxosmithkline neuraminidase inhibitor approve fda drug deliver inhaled powder direct competition tamiflu tamiflu currently fdaapprove neuraminidase inhibitor available pill believe method delivery give tamiflu competitive advantage relenza aware biocryst pharmaceutical develop neuraminidase inhibitor peramivir potential deliver oncedaily pill tamiflu take twice daily treatment flu biocryst pharmaceutical receive approval product direct competition tamiflu competition tamiflu market alternative influenza vaccination believe influenza vaccination remain effective method prevent flu vistide vistide antiviral medication treatment cmv retinitis patient aid cmv retinitis condition cause viral infection characterize lesion form patient retina condition affect person weaken immune system common patient aid leave untreated cmv retinitis lead blindness vistide approve fda june european regulatory authority base clinical trial demonstrate drug delay progression cmv retinitis lesion newly diagnose patient previously treat patient fail therapy sell vistide sale force marketing sale outside pharmacia corporation exclusive right sell vistide vistide approve sale country european union country world pharmacia corporation pay percentage revenue generate sale vistide collaborative relationshipspharmacia corporation vistide compete number drug treat cmv retinitis drug include ganciclovir drug sell intravenous oral formulation hoffman laroche ocular implant bausch lomb incorporate valganciclovir oral prodrug formulation ganciclovir market hoffman laroche foscarnet intravenous drug sell astrazeneca formivirsen drug inject directly eye sell cibavision competition significant effect associate use vistide kidney toxicity effect certain precaution take vistide certain circumstance vistide time vistide give patient patient test warning sign kidney toxicity patient warning sign kidney toxicity vistide give patient combination certain solution reduce possibility kidney toxicity addition vistide give patient receive drug cause kidney toxicity patient receive drug know cause kidney toxicity discontinue take drug wait seven day vistide certain animal study cidofovir active ingredient vistide cause cancer effect dose limitation competitive disadvantage vistide cidofovir active agent vistide consider government strategy deal potential bioterror attack involve smallpox lifethreatene infectious disease laboratory test cidofovir demonstrate activity strain virus cause smallpox current clinical trial diluted smallpox vaccine conduct national institute allergy infectious disease cidofovir potential treatment vaccinia infection potential adverse reaction cause smallpox vaccine additionally national institutes health hold ind allow emergency use cidofovir smallpox outbreak predict country stockpile vistide treatment smallpox exclusive worldwide license patent right relate technology cidofovir iocbrega obligate pay net revenue sale vistide product contain cidofovir iocbrega collaborative relationshipsiocbrega daunoxome daunoxome liposomal formulation anticancer agent daunorubicin receive approval sell daunoxome country line therapy treat patient suffer certain type hivassociate kaposi sarcoma kaposi sarcoma disease characterize widely disseminate lesion theskin mucous membrane lymph node viscera life threaten patient suffer aid daunoxome use proprietary liposomal technology deliver safe effective dose daunorubicin disease site study show daunoxome actually locate accumulate patient tumor allow patient receive high concentration daunorubicin disease site obtain equivalent dose nonliposomal daunorubicin market daunoxome abroad sale force certain foreign country distributor marketing sale product late stage clinical trial develop adefovir dipivoxil large latestage human clinical trial treat patient infect hbv base result date apply approval adefovir dipivoxil treatment hbv infection european union march exclusive commercial right market cidecin european country cidecin antibacterial develop cubist pharmaceuticals inc phase phase iii clinical trial cubist complete successful pivotal phase iii clinical trial treatment complicated skin soft tissue infection cause grampositive bacteria pivotal phase iii clinical trial treatment communityacquire pneumonia cause gram positive bacteria cidecin successful meeting primary endpoint evaluating strategy apply regulatory approval cidecin europe currently expect file application determine certainty ongoing future clinical trial adefovir dipivoxil cidecin successful successful fda regulatory agency approve drug marketing adefovir dipivoxil hepatitis hepatitis cause highly contagious hbv hbv infection cause acute liver failure patient develop chronic hbv infection year lead complication cirrhosis liver cancer liver failure result death accord current estimate world health organization center disease control approximately million people worldwide million people chronic hbv infection million death attributable hbv infection worldwide year hepatitis lead cause death worldwide adefovir dipivoxil nucleotide analogue reverse transcriptase inhibitor adefovir dipivoxil disable hbv interfere activity enzyme know hbv polymerase necessary hbv replicate separate phase iii clinical trial evaluate safety effectiveness adefovir dipivoxil pill treat patient chronic hbv infection phase iii trial design randomize doubleblind placebocontrolle study conduct clinical site canada europe australia southeast asia study evaluate adefovir dipivoxil treat patient test positive hbv antigen common type chronic hepatitis trial study evaluate adefovir dipivoxil daily treat patient type hbv know precore mutant hepatitis precore mutant hbv common southeast asian mediterranean countries june november respectively announce interim complete analysis week effectiveness safety result study week pivotal phase iii clinical trial evaluate safety effectiveness adefovir dipivoxil dose daily monotherapy compare placebo patient chronic hbv infection hbv antigen positive site united states canada europe australia southeast asia design study provide data safety effectiveness dose adefovir dipivoxil secondary objective dose adefovir dipivoxil study patient randomly divide group approximately equal size group receive dose adefovir dipivoxil group receive dose adefovir dipivoxil group receive placebo result adefovir dipivoxil daily dose demonstrate follow week treatment adefovir dipivoxil improve liver histology patient compare patient receive placebo meet primary endpoint trial change liver histology important marker disease progression patient chronic hbv infection adefovir dipivoxil cause seroconversion disappearance hepatitis antigen marker hbv replication appearance antibodie specific antigen patient treat adefovir dipivoxil week compare patient placebo adefovir dipivoxil reduce patient serum hbv dna measure hbv average approximately log copiesml meet endpoint trial compare reduction approximately log copiesml patient receive placebo adefovir dipivoxil reduce amino alanine transferase alt level iul compare reduction iul patient receive placebo fortyeight percent patient treat adefovir dipivoxil achieve normalization alt level compare patient receive placebo alt level indicator disease severity adefovir dipivoxil cause significant increase effect relative placebo evidence kidney abnormality adefovir dipivoxil placebo group similar discontinuation rate patient adefovir dipivoxil patient placebo patient receive adefovir dipivoxil observe develop resistance mutation adefovir september announce week preliminary effectiveness safety result study week pivotal phase iii clinical trial evaluate safety effectiveness adefovir dipivoxil dose daily monotherapy compare placebo patient precore mutant hbv hbv antigennegative virus compensate liver function liver function near normal level site australia canada france greece israel italy southeast asia design study provide conclusive data safety effectiveness daily dosage adefovir dipivoxil precore mutant hbv study patient randomly divide group group patient treat adefovir dipivoxil daily twothird enrol patient group patient give placebo onethird enrol patient result demonstrate follow week treatment adefovir dipivoxil daily dose adefovir dipivoxil improve liver histology patient compare improvement patient receive placebo meet primary endpoint trial change liver histology important marker disease progression patient chronic hbv infection adefovir dipivoxil reduce patient serum hbv dna average approximately log copiesml meet endpoint trial compare reduction approximately log copiesml patient receive placebo adefovir dipivoxil reduce alt level iul compare reduction iul patient receive placebo seventytwo percent patient treat adefovir dipivoxil achieve normalization alt level compare patient receive placebo alt level indicator disease severity adefovir dipivoxil cause significant increase effect relative placebo evidence kidney abnormality adefovir dipivoxil placebo group equivalent discontinuation rate patient adefovir dipivoxil patient placebo patient receive adefovir dipivoxil observe develop resistance mutation adefovir vaccine available prevent transmission hbv cure patient chronically infect virus expect vaccine widely available incidence new hbv infection decrease exist therapy treat patient infect hbv include drug epivirhbv form lamivudine sell glaxosmithkline introna form interferon alpha sell schering plough epivirhbv orally administer antiviral drug prevent hbv replicating patient introna injectable drug provide reduction virus blood patient associate effect believe fda approve adefovir dipivoxil epivirhbv significant competition certain adefovir dipivoxil approve treatment hbv infection determine adefovir dipivoxil competitive epivirhbv competition case hiv infection drug resistance problem drug treat hbv infection example year therapy epivir hbv patient develop resistance lamivudine increase year therapy base publish datum lamivudine resistance occur percent hivhbv coinfecte patient year lamivudine therapy percent patient treat year conduct provide support clinical trial design provide information adefovir dipivoxil provide treatment option patient lamivudine resistant hbv infection data clinical study patient lamivudineresistant hbv infection treat adefovir dipivoxil daily demonstrate treat patient lamivudineresistant hbv infection adefovir dipivoxil reduce serum hbv dna level study patient lamivudineresistant chronic hbv infection compensate liver function liver function normal near normal level reduction week serum hbv dna patient treat adefovir dipivoxil log copiesml similar patient treat adefovir dipivoxil combination lamivudine daily log copiesml great patient treat lamivudine daily log copiesml study liver transplant patient lamivudineresistant chronic hbv infection treat adefovir dipivoxil week serum hbv dna level reduce log copiesml week log copiesml weeks administration adefovir dipivoxil sustained reduction week median reduction hbv dna log copiesml study patient lamivudineresistant chronic hbv infection decompensate liver disease liver long function normally lead sign symptom liver disease treat adefovir dipivoxil add ongoing lamivudine treatment median reduction serum hbv dna approximately log copiesml week treatment study week treatment adefovir dipivoxil add exist lamivudine therapy patient coinfecte lamivudineresistant chronic hbv hiv infection statistically significant mean reduction serum hbv dna log copiesml study patient marker indicate abnormal liver function prior treatment show improvement clinical marker liver function treatment adefovir dipivoxil available data date demonstrate resistancemutation associate adefovir dipivoxil hbv suggest development resistance adefovir dipivoxil hbv patient slow infrequent believe resistance profile adefovir dipivoxil important drug treat chronic hbv infection certain resistance datum obtain continue phase iii clinical trial adefovir dipivoxil continue resistance characteristic describe viread discontinue development adefovir dipivoxil treatment hiv infection safety benefit concern arise study study show adefovir dipivoxil significantly effective hbv hiv allow use low dose treatment hiv infection dose adefovir dipivoxil show significant kidney toxicity clinical trial date clinical datum phase iii clinical trial dose adefovir dipivoxil demonstrate dose meet primary endpoint study certain result phase iii clinical study adefovir dipivoxil dose demonstrate satisfaction fda regulatory agency adefovir dipivoxil safe effective treatment chronic hbv infection hepatitis infection common china southeast asian country december receive clinical trial permit initiate phase clinical trial china commence clinical trial june limited regulatory expertise china manufacturing marketing capacity china southeast asia continue rely assistance party activity difficult protect patent country adversely affect unable obtain adequate patent protection adefovir dipivoxil china southeast asia approval commence phase clinical trial china adefovir dipivoxil grant class designation adefovir dipivoxil ultimately approve sale chinawould year market exclusivity adefovir dipivoxil respect competitor able begin clinical development adefovir dipivoxil follow approval exclusive worldwide license patent right relate technology adefovir dipivoxil iocbrega obligate pay net revenue sale adefovir dipivoxil iocbrega country product patent protection include member states european union collaborative relationshipsiocbrega cidecin cidecin daptomycin injection investigational antibacterial compound develop cubist pharmaceuticals inc january enter agreement cubist grant exclusive commercial right cidecin european country arrangement cubist responsible ongoing clinical trial product responsible european regulatory filing country exclusive commercial right believe arrangement represent strategic opportunity cidecin fall therapeutic focus antiinfective product approve sell expand version exist european sale marketing infrastructure laboratory test suggest cidecin effective rapidly kill grampositive bacteria include resistant current therapy grampositive bacterial infection include complicated skin soft tissue infection bacteremia endocarditis infection valve heart complicated urinary tract infection pneumonia osteomyelitis infection bone bone marrow case hiv hbv resistance exist antibacterial therapy significant problem treat infection laboratory test confirm clinical trial cidecin useful drug treat infection assurance result complicated skin soft tissue infection confirm clinical trial cubist evaluate currently evaluate cidecin multiple phase phase iii trial treatment complicated skin soft tissue infection communityacquire pneumonia resistant enterococcal infection complicate urinary tract infection complete pivotal phase iii trial treatment complicated skin soft tissue infection cause grampositive bacteria cidecin achieve primary endpoint statistical equivalence comparator agent currently consider optimal antibiotic standard care complicated skin soft tissue infection data trial demonstrate patient successfully treat cidecin require few day intravenous therapy patient successfully treat comparator agent cidecin safety profile similar comparator agent january cubist announce primary endpoint demonstrate noninferiority active comparator agent achieve cubist phase iii trial investigate safety effectiveness cidecin treatment communityacquire pneumonia require hospitalization february cubist announce result phase clinical trial cidecin demonstrate primary endpoint demonstrate difference microbiologic clinical cure rate cidecin versus comparator agent achieve treatment complicated urinary tract infection cause grampositive bacteria march cubist announce soon begin phase iii clinical trial cidecin treatment endocarditis infection heart valve bacteremia infection bloodstream cubist state intend file nda cidecin indication complicated skin soft tissue infection involve susceptible resistant grampositive organism agreement cubist require cubist continue conduct complete additional clinical trial cubist successfully complete phase iii clinical trial use complicated skin soft tissue infection seek regulatory approval use territory exclusive commercial right indication territory predict outcome clinical trial cidecin cubist evaluate cidecin additional use currently evaluate option filing marketing authorization cidecin european union receive indication regulatory authority european union application seek marketing approval cidecin single indication treatment complicate skin soft tissue infection approved currently expect file application accurately predict cidecin meet primary endpoint clinical trial indication complicated skin soft tissue infection conduct cubist able obtain regulatory approval cidecin europe file marketing authorization application cidecin europe approve sell cidecin european sale marketing infrastructure cubist develop oral formulation daptomycin human clinical trial agreement cubist exclusive commercial right territory oral formulation daptomycin develop cubist require pay milestone payment cubist base certain development goal relate clinical development regulatory approval cidecin oral formulation daptomycin require pay royalty cubist base sale cidecin oral formulation daptomycin collaborative relationshipscubist product preclinical development intend begin phase clinical trial novel nucleotide analogue reverse transcriptase inhibitor viread process body yield active chemical tenofovir cell chemical composition allow cross cell membrane easily viread tenofovir present high level cell result great potency viread inhibit lowlevel hiv replication cell difficult reach reverse transcriptase inhibitor certain phase clinical trial subsequent phase phase iii clinical trial conduct complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk appear sufficient treatment benefit science research scientist foster city san dimas california engage discovery development new molecule technology hope lead new medicine novel formulation exist drug therapeutic focus area infectious disease total research development expense million compare million million nucleotide analogues scientist work proprietary nucleotide analogue develop treatment viral infection compound treat viral infection interfere activity certain enzyme necessary virus grow example vistide nucleotide analogue cytosine inhibit activity enzyme cmv essential virus spread viread adefovir dipivoxil nucleotide analogue work inhibit activity reverse transcriptase enzyme necessary replication hiv viread hbv adefovir dipivoxil believe small molecule nucleotide analogue offer advantage therapeutic advantage include molecule demonstrate ability work infect uninfected cell enable develop drug treat patient infected virus prevent healthy person infect place drug develop molecule show treatment activity patient long period time available drug enable develop drug require frequent dose convenient patient give complexity drug development certain drug candidate develop science advantage develop drug candidate advantage fda regulatory agency reject marketing approval drug candidate reason include safety benefit concern liposome scientist focus apply proprietary liposomal drug delivery technology develop safe effective convenient drug liposome submicroscopic structure phospholipid basic component human cell wall hollow sphere drug pack believe influence way compound release distribute body place liposome turn improve safety treatment benefit compound example develop ambisome incorporate amphotericin liposome preclinical study show ambisome deliver amphotericin manner result few effect improve treatment benefit conventional amphotericin include concentrate drug site infection extend time drug remain blood stream prolong therapeutic effect reduce kidney toxicity injection relate reaction clinical study demonstrate ambisome persist long blood stream low kidney toxicity injection relate reaction compare conventional amphotericin current strategy use liposomal technology compound develop internally identify appropriate compound develop party use technology compound develop party appropriate technology include like amphotericin prove therapeutic benefit suffer significant effect suffer dose administration problem believe use liposomal technology improve safety drug maintain improve therapeutic benefit identify certain generic compound compound protect patent proprietary compound own party benefit substantially liposomal technology begin formulation study compound addition discuss continue discuss collaborative relationship company develop liposomal formulation compound hiv protease inhibitor evaluate number small molecule compound know protease inhibitor potential treatment hiv infection protease inhibitor act interfere activity protease enzyme like reverse transcriptase necessary replication hiv conduct number preclinical experiment compound demonstrate potent antiviral activity scientist try increase safety convenience reduce resistance concern compound antiviral research undertake additional research area treatment viral disease effort focus potential target hiv therapeutic drug marketing sale establish sale force therapeutic specialist begin sell vistide marketing subsidiary united kingdom germany italy spain france portugal greece netherlands australia sale professional promote sell viread ambisome daunoxome europe ambisome daunoxome australia vistide ambisome sell fujisawa copromote product canada pharmacia corporation promote sell vistide country outside hoffmannla roche promote sell tamiflu sell sale force promote viread vistide direct contact physician hospital clinic healthcare provider involve treatment patient hiv ambisome infectious disease specialist hospital home health care provider cancer specialist daunoxome cancer specialist hospital sale force support field support force marketing sale support staff base headquarters foster city california international sales force europe australia international marketing subsidiary head general manager oversee operation market serve subsidiary personnel locate mainly europe include medical financial regulatory manufacturing human resource personnel support international sale marketing operation subsidiary assist obtain regulatory approval country locate sell viread vistide daunoxome viread ambisome daunoxome europe wholesaler specialty distributor turn sell product physician hospital clinic pharmacy healthcare provider country outside agreement thirdparty distributor include distributor certain country market operation promote sell distribute ambisome daunoxome international distribution agreement generally provide distributor exclusive right sell ambisome daunoxome particular country country specify period time intend enter similar arrangement thirdparty distributor outside promotion sale anddistribution viread increase sale force devote additional marketing resource approval viread expand coverage healthcare professional treat hivinfecte patient significantly increase size commercial operation europe manage commercialization viread european union current intention retain commercial right adefovir dipivoxil hbv infection europe sell marketing partner distributor asia rest world retain significant commercial right adefovir dipivoxil hbv infection product approve need use additional marketing resource sell product cidecin approve marketing europe believe give profile product target market additional sale marketing position need add viread vistide returnable original unopened container year expiration date damage receive customer customer return ambisome daunoxome shelf life expire product damage defective customer receive ambisome approve shelf life month month european country daunoxome shelf life week european country viread shelf life month approve shelf life european union additionally certain governmental agency customer state aids drug assistance program entitle receive discount require provide rebate state medicaid programs date return rebate discount material fujisawa establish return policy ambisome north america hoffmannla roche establish return policy tamiflu collaborative relationship business strategy establish collaboration company assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire company product right product technology complementary business accounting relationship find note consolidated financial statement exist collaborative relationship follow hoffmannla roche september enter collaboration agreement hoffmannla roche develop commercialize therapy treat prevent flu agreement grant hoffmannla roche exclusive worldwide right proprietary influenza neuraminidase inhibitor include tamiflu october fda approve tamiflu marketing november hoffmannla roche begin sell tamiflu december receive license fee milestone payment hoffmannla roche total million relate execution agreement regulatory filing approval tamiflu hoffmannla roche fund research development cost tamiflu include reimbursement million period january december addition agreement hoffmannla roche responsible pricing promote sell tamiflu worldwide basis hoffmannla roche pay percentage net revenue sale tamiflu certain circumstance hoffmannla roche pay reduce example cost material use manufacture tamiflu increase receive payment recognize revenue hoffmannla roche quarter follow quarter sale hoffmannla roche milestone payment tamiflu approve sale european union agreement hoffmanla roche terminate countrybycountry basis later expiration patent coverage tamiflu year commercial sale hoffmannla roche right terminate agreement entirety countrybycountry basis prior expiration time month notice fujisawa enter agreement fujisawa provide exclusive right promote sell ambisome country canada fujisawa exclusive right promote sell ambisome canada right copromote ambisome fujisawa fujisawa primary responsibility promote sell ambisome receive approximately net revenue sale ambisome copromotion effort receive payment recognize revenue fujisawa month follow month fujisawa sale require pay fujisawa revenue connection sale ambisome significant asian market include japan korea taiwan china india manufacture ambisome sale fujisawa purchase ambisome sale price equal cost manufacture product sale canada cost plus specify percentageour agreement fujisawa terminate patent cover ambisome japan expire iocbrega enter agreement iocbrega relate nucleotide compound discover institution december pay iocbrega million reduce royalty payable sale viread adefovir dipivoxil royalty rate european union country product approve patent protection agreement amendment agreement receive iocbrega exclusive right manufacture use sell nucleotide compound cover agreement country patent protection require pay iocbrega net revenue generate sale viread adefovir dipivoxil net revenue generate sale vistide product contain compound subject minimum royalty payment country patent protection require pay royalty iocbrega sale viread adefovir dipivoxil require pay net revenue generate sale vistide product contain compound currently make quarterly payment iocbrega base percentage sale vistide viread pay additional amount commercial sale adefovir dipivoxil amortize million payment december estimate commercial life viread adefovir dipivoxil reduce report earning product agreement iocbrega terminate countrybycountry basis later expiration patent coverage product license agreement year commercial sale iocbrega terminate license agreement particular product key market sale product month regulatory approval country cubist january enter agreement cubist give exclusive commercial right european country oral injectable formulation cubist investigational antibacterial compound daptomycin formulation include cidecin intravenous formulation daptomycin currently phase iii clinical trial treatment bacterial infection agreement cubist require complete certain key clinical trial cidecin responsible regulatory filing product territory cidecin approve marketing territory responsible marketing cidecin territory pay upfront fee cubist million time sign agreement pay milestone payment cubist total million achievement milestone relate safety effectiveness cidecin treatment complicated skin soft tissue infection cause grampositive bacteria require additional payment cubist million certain goal relate clinical development regulatory approval cidecin oral formulation daptomycin achieve require pay cubist percentage revenue sale daptomycin product territory cubist desire grant commercial right oral injectable daptomycinrelate product certain country include country join cubist offer commercial right priority basis cubist obligate continue preclinical development oral formulation daptomycin obligation pursue clinical development formulation appropriate agreement expire country country basis respect product develop later year commercial sale product country date patent coverage product pharmacia corporation august enter agreement pharmacia corporation relate vistide agreement receive million signing million approval vistide marketing europe addition agreement pharmacia corporation exclusive right market sell vistide country outside right negotiation competitive product responsible maintain patent cidofovir require sell bulk cidofovir pharmacia corporationwe require sell bulk cidofovir pharmacia corporation pharmacia corporation pay percentage net sale vistide product develop collaboration agreement receive payment recognize revenue pharmacia corporation quarter follow quarter sale pharmacia corporation hold share common stock purchase connection agreement pharmacia corporation sell share acquire additional share stock approval june agreement pharmacia corporation expire countrybycountry basis patent coverage vistide expire year commercial sale vistide country product cover patent addition pharmacia corporation terminate agreement month notice notice countrybycountry basis month apply marketing approval competitive product sumitomo pharmaceutical ltd enter agreement sumitomo pharmaceutical ltd give sumitomo exclusive right develop market ambisome japan sumitomo pay million time enter agreement million march sumitomo regulatory filing japan term agreement sumitomo require payment million ambisome approve sale japan sumitomo require pay percentage revenue generate sale ambisome ambisome approve sale japan manufacture ambisome sale sumitomo japan price charge sumitomo supply ambisome percentage revenue required pay determined price ambisome japan agreement terminate later year sumitomo begin sell ambisome japan date patent ambisome japan expire eyetech pharmaceutical march enter agreement eyetech pharmaceuticals inc relate know eye oligonucleotide eyetech currently develop treatment agerelate macular degeneration receive million upfront license fee eyetech execution agreement term agreement eyetech receive exclusive right develop commercialize eye entitle additional cash payment eyetech million eyetech reach certain eye development milestone product successfully commercialize eyetech pay royalty worldwide sale product transaction receive fiveyear warrant purchase share eyetech series convertible prefer stock exercisable price share price stock issue investor require license agreement university technology corporation transfer warrant university technology corporation right acquire share currently hold warrant purchase share agreement expire later year commercial sale product develop date patent expire agreement glaxosmithklineselex enter agreement give glaxosmithkline nonexclusive right use selex technology year identify aptamer agreement glaxosmithkline required pay fee time enter additional agreement glaxosmithkline require payment base achieve certain goal relate regulatory approval product develop base aptamer glaxosmithkline required pay percentage revenue generate sale product develop base theglaxosmithkline require pay percentage revenue generate sale product develop base aptamer agreement terminate glaxosmithkline extend agreement additional year period case glaxosmithkline required pay appropriate fee glaxosmithkline terminate agreement early time day notice somalogic inc november enter agreement somalogic inc company form larry gold founder nexstar pharmaceuticals inc nexstar relate selex technology agreement give somalogic exclusive right use selex technology sell vitro diagnostic product diagnostic product person animal assign sell somalogic certain patent material relate vitro diagnostic include robotic selex machine right use drug discovery technology subject agreement internally study disease drug development clinical trial program somalogic pay installment fee time enter agreement second final installment november agreement terminate late country country basis patent coverage drug discovery technology expire november archemix corporation october enter agreement archemix corporation relate selex technology agreement give archemix exclusive right selex process include therapeutic commercial application extent license preexist agreement right use selex technology internal research purpose archemix pay million require pay million require license agreement university technology corporation pay million payment pay million payment university technology corporation receive warrant purchase archemix stock require license agreement university technology corporation transfer warrant university technology corporation osi pharmaceuticals inc november enter agreement osi pharmaceuticals inc sale osi oncology asset transaction complete december record gain million agreement sell osi pipeline clinical candidate oncology relate intellectual property boulder colorado operation include clinical research drug development operation infrastructure facility clinical development candidate sell osi liposomal lurtotecan nucleoside analogue liposomal thymidylate synthase inhibitor osi pay million cash approximately million share osi common stock entitle additional payment osi million cash combination cash osi common stock osi reach certain development milestone advanced oncology product candidate sell osi manufacturing agreement produce osi liposomal formulation liposomal product sell osi manufacturing facility san dimas california osi assume right obligation amend agreement glaxo wellcome glaxosmithkline glaxo relate license agreement glaxo relate license agreement relate southern research institute international distribution agreement agreement distributor europe asia latin america middle east africa grant distributor exclusive right sell ambisome case daunoxome particular country country specify period time agreement provide collaborative effort distributor obtain regulatory approval product particular country marketing product country agreement establish price distributor pay product require deliver quantity product order distributor intend enter similar distribution agreement viread country promote sell directly academic consulting relationshipsto supplement research development effort regular business enter arrangement university medical research institution arrangement provide right patent patent application technology own institution return payment fee relate use right university technology corporation ongoing collaborative arrangement relate selex technology university technology corporation technology hold company university colorado boulder arrangement university colorado boulder give present future right invention cover patent patent application selex technology improvement selex technology make discover oligonucleotide molecule make selex technology result certain research computer software relate selex technology require pay university colorado boulder revenue generate sale selexderive product amount receive party base sale party selexderive product payment receive party result certain arrangement party develop sell selexderive product manufacture ambisome daunoxome manufacture ambisome daunoxome commercial quantity separate adjacent facility san dimas california ambisome produce building daunoxome produce separate building medicine control agency united kingdom food drug administration approve commercial production ambisome daunoxome facility produce import ambisome daunoxome european union manufacturing facility dublin ireland perform quality control testing final labeling package european union use commercially available material equipment manufacture product currently obtain amphotericin use manufacture ambisome daunorubicin hcl distearoylphosphatidylcholine use manufacture daunoxome cholesterol use manufacture ambisome daunoxome single approve supplier ambisome currently freeze dry san dimas manufacturing facility sell freezedrie product give demand projection growth ambisome use currently party fill freeze dry product evaluate feasibility instal additional freeze drying capacity san dimas unable locate appropriate party install validate additional freeze drying capacity san dimas ability increase ambisome sale diminish manufacture liposomal product particularly complex process new liposomal product develop require unique complex variation manufacturing process antiviral product hire party manufacture antiviral drug clinical commercial purpose include vistide adefovir dipivoxil viread hoffmannla roche manufacture tamiflu commercialscale manufacturing facility antiviral product qualify fda current good manufacturing practice current plan establish facility party certain perform obligation effectively timely basis party perform effectively timely clinical trial regulatory filing delay unable deliver product customer timely basis adversely affect operating result january hoffmannla roche announce production problem liquid suspension form tamiflu approve treatment child young year old available expect available flu season supplier approve fda manufacture cidofovir vistide supplier approve european union manufacture cidofovir use vistide second cidofovir supplier qualified assure supply single fda emea approve supplier final drug product manufacture active ingredient viread contract manufacturer approve fda european union manufacture viread tablet contract manufacturer approve agency second contract manufacturer qualified manufacture viread tablet assure supply seek qualification theeuropean union contract manufacturer active ingredient adefovir dipivoxil contract manufacturer final adefovir dipivoxil drug product commercial supply manufacture site use interrupted reason ability ship product impair adversely affect viread adefovir dipivoxil tablet clinical trial manufacture contract manufacturing site manufacture site interrupt reason ability maintain clinical supply impair adversely affect future antiviral product need develop additional manufacturing capability establish additional party supplier order manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity candidate approve commercial sale unable develop manufacturing capability internally contract large scale manufacturing party acceptable term future antiviral product ability conduct largescale clinical trial meet customer demand commercial product adversely affect believe technology use manufacture product compound proprietary antiviral product disclose necessary aspect technology contract manufacturer enable manufacture product compound agreement manufacturer intend restrict reveal technology certain manufacturer comply restriction addition manufacturer develop technology relate work perform need manufacture product compound require enter agreement manufacturer want use technology allow manufacturer use technology manufacturer refuse allow use technology demand term use technology acceptable believe compliance material environmental regulation relate manufacture product patent proprietary right patent proprietary right important business properly design enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection internationally file additional patent application appropriate cover improvement compound product technology rely trade secret internal knowhow technological innovation agreement party develop maintain protect competitive position ability competitive depend success strategy number patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show actual estimate expiration date europe primary patent patent issue pende application cover compound market product product candidate patent expiration european patent expiration product viread ambisome tamiflu vistide daunoxome product candidate adefovir dipivoxil cidecin application patent pende patent application issue patent protection date indicate instead rely patent expire early example european patent viread issue patent expire provide protection commercial right cidecin united states method use patent general method use patent provide level protection composition matter patent patent cover vistide viread adefovir dipivoxil cidecin hold party acquire exclusive right patent agreement party collaborative relationship patent cover active ingredient ambisome daunoxome instead hold patent liposomal formulation compound protect formulation trade secret patent filing cover form adefovir dipivoxil china certain asian country application pende asian country include china relate specific form formulation adefovir dipivoxil asia major market hbv therapy obtain patent compound year obtain marketing approval limit time prevent company develop compound reduce value product apply patent term extension example extension patent vistide grant number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain important infringe patent proprietary right violate agreement grant proprietary right infringe patent violate agreement prevent develop selling product process cover patent agreement require obtain license party allow use technology certain require obtain license party technology obtain reasonable cost able obtain require license adversely affect patent application confidential period time include patent issue pende patent application patent eventually issue prevent develop sell certain product obtain license use patent technology patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation reexamination proceeding enforcement validity exist patent future patent invalidate patent substantially reduce protection addition pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product develop rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor research development agreement invention discover certain case jointly own corporate partner case exclusive property difficult determine own particular invention dispute arise invention competition product development program target number disease condition include viral fungal bacterial infection commercially available product disease large number company institution spend considerable amount money resource develop additional product treat disease current product compete available product base primarily product performance safety tolerability acceptance doctor patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing adaptability mode dose product market future compete product offer competitor competitor introduce datum show improved characteristic product improve increase marketing effort simply low price product sale product decrease certain product develop future compare favorably product offer competitor exist future product compare favorably new product develop competitor ability competitive depend ability attract retain qualified personnel obtain patent protection develop proprietary product process secure sufficient capital resource substantial period take develop product ambisome current expect competitor conventional amphotericin market ambisome approve line therapy conventional amphotericin bristol myers squibb company numerous generic manufacturer country ambisome prescribed conventional amphotericin therapy fail caspofungin product develop merck receive marketing approval january sell cancidas receive marketing approval european union october expect face significant competition caspofungin voriconazole develop pfizer inc receive marketing approval european union march pfizer file application marketing approval voriconazole fda deem nda approvable expect face significant competition voriconazole lipidbase amphotericin product approve europe include abelcet sell elan corporation amphotecother lipidbase amphotericin product approve europe include abelcet sell elan corporation amphotec sell intermune pharmaceutical inc product compete ambisome primary secondary therapy generally offer price ambisome price viread face substantial competition number drug treat hiv infection aid currently sell advanced stage clinical development include product currently sell major pharmaceutical company significant competitor hivaid market glaxosmithkline bristolmyers squibb hoffmannla roche pfizer merck boehringeringelheim abbott laboratories tamiflu competes relenza antiflu drug sell glaxosmithkline relenza neuraminidase inhibitor deliver orallyinhale dry powder addition biocryst pharmaceutical develop neuraminidase inhibitor antiflu drug peramivir represent significant competition fda approve drug administer oncedaily pill oppose tamiflu take twice daily treatment certain tamiflu compare favorably drug base performance price length dose effect criterion biocryst pharmaceuticals commence phase iii clinical trial peramivir unclear product market vistide compete number drug treat cmv retinitis drug include ganciclovir widely prescribe drug treatment cmv retinitis sell hoffman laroche intravenous formulation treatment cmv retinitis oral formulation prevention treatment cmv retinitis bausch lomb incorporate device implant patient infected eye release ganciclovir directly infect area valganciclovir oral prodrug formulation ganciclovir market hoffman laroche receive marketing approval april netherlands september treatment cmv retinitis hoffman laroche state expect paneuropean approval mid foscarnet injectable drug treatment cmv retinitis sell astrazeneca formivirsen drug inject directly eye sell cibavision adefovir dipivoxil approve treat hbv infection lamivudine significant competition lamivudine drug develop glaxosmithkline collaboration biochem pharma lamivudine sell europe china country show effective treat patient infect hbv drug approve await approval treatment kaposi sarcoma europe include sell liposomal formulation drug compete expect compete daunoxome number company pursue development technology competitive research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently biopharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program anticipate face increase competition future competitor introduce new product market new technology available determine exist product new product competitor develop effective effectively market sell develop competitive product render technology product obsolete noncompetitive recover money resource develop product government regulation operation activity subject extensive regulation numerous government authority countrie drug subject rigorous fda regulation federal food drug cosmetic act federal state statute regulation govern testing manufacture safety effectiveness labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume fda approve drug sell general process approval follow preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug potential safety benefit submit datum fda investigational new drug application ind seek approval test compound human clinical trial fda accept investigational new drug application study drug human clinical trial determine drug safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug give small number healthy human subject patient test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug give limited patient population determine effect drug treating disease well dose drug possible effect safety risk drug phase iii compound appear effective safe phase clinical trial phase iii clinical trial commence confirm result phase iii clinical trial longterm involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug uncommon drug appear promise phase clinical trial fail rigorous reliable phase iii clinical trial fda approval process believe datum phase iii clinical trial adequate level safety effectiveness file nda fda seek approval sell drug particular use fda review new drug application hold public hear independent advisory committee expert advisor ask additional question drug committee make recommendation fda bind fda generally follow fda fda agree compound require level safety effectiveness particular use allow sell drug use unusual fda reject application believe drug safe effective believe datum submit reliable conclusive point process development drug stop number reason include safety concern lack treatment benefit certain clinical trial conduct include viread hiv infection adefovir dipivoxil chronic hbv infection conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require complete additional testing provide additional data information improve manufacturing process procedure facility require extensive postmarketing test surveillance monitor safety benefit product candidate determine new drug application contain adequate evidence safety benefit drug addition fda approve drug limit use drug approval withdraw fda believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug manufacturing facility drug sell include company manufacture drug approve fda subject periodic inspection fda foreign establishment manufacture product sell approve fda subject periodic regulatory inspection manufacturing facility locate california include san dimas facility foster city facility license state california compliance local regulatory requirement drug treat lifethreatening disease condition adequately address exist drug designate fast track product fda eligible priority month review accelerate approval case viread drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug seek priority month review accelerate approval adefovir dipivoxil determine grant impact time likelihood approval adefovir dipivoxil subject federal state local regulation workplace safety protection environment use hazardous material chemical viruse radioactive compound research development activity eliminate risk accidental contamination injury material misuse accident involve material lead significant litigation fine penalty drug subject extensive regulation outside european union centralize approval procedure authorize marketing product country european union include major country europe procedure decentralized system approval country european union obtain approval country european union simplify application process approval centralized procedure pricing reimbursement approval require country vistide viread approve european union centralize procedure centralized approval procedure adefovir dipivoxil tamiflu review centralized procedure approve europe pricing reimbursement insurance company health maintenance organization hmos thirdparty payor government seek limit charge drug example certain foreign market pricing negotiation require obtain approval product expect continue number federal state proposal implement drug price control addition manage care organization common continue seek low drug price announcement proposal effort cause stock price low proposal adopt revenue decrease ability sell drug depend availability reimbursement government private insurance company government insurance company demand rebate predetermine discount list price expect product develop particularly aid indication subject reimbursement issue certain product obtain regulatory approval reimburse government insurance company regulatory approval price generally require foreign country particular certain country condition approval product agreement seller sell product certain price country past require price reduction connection product approval certain regulatory authority future establish low price regulatory action reduce price product country practical effect require reduce price country certain develop country significantly affect hiv aids parallel import generic competition occur adversely affect revenue sale market share vireademployee february fulltime employee believe good relation employee risk factor evaluate business carefully consider follow risk addition information report follow risk materially adversely affect business operating result financial condition viread new drug gain significant market acceptance viread new drug face extremely competitive marketplace currently drug sell treatment hiv infection aid potential drug late stage clinical development competitor potential competitor substantially great resource resource include great experience promote market hiv drug superior product development capabilitie financial scientific manufacturing marketing managerial human resource order viread successful establish marketplace competitor drug early determine viread achieve significant market acceptance market sell drug treatment hiv infection successful operate manage marketing sale operation size attempt penetrate potential market size effectively predict phase iii clinical study demonstrate viread safe effective combination therapy patient prior hiv therapy compare competitor drug long term use viread reveal safety issue development resistance viread patient marketing effort unsuccessful clinical trial result demonstrate viread safe effective patient prior hiv therapy viread turn safety resistance issue unsuccessful convincing physician prescribe viread patient government reimburser private insurance company pay viread prescribe patient prior hiv therapy viread gain significant market acceptance result operation suffer significant reduction ambisome viread sale significantly reduce operating income require scale manufacturing operation reduce sale force ambisome sale year end december approximately million million million total revenue expect revenue sale ambisome continue constitute substantial total product revenue viread sale year end december approximately million total revenue represent sale access program europe initial product sale follow regulatory approval viread october expect product sale viread constitute substantial total revenue foreseeable future accordingly foreseeable future expect continue rely heavily sale ambisome viread support exist manufacturing sale infrastructure provide operating income offset significant portion administrative research development expenditure significant reduction sale ambisome viread result introduction competitive product hurt business scale manufacturing operation reduce sale force product market compete ambisome generally price lower ambisome expect face significant competition new antifungal product include caspofungin product develop merck voriconazole product develop pfizer inc merck receive marketing approval january european union marketing approval october caspofungin pfizer receive european union marketing approval march file marketing approval application deem approvable fda viread face competition number drug treat hiv infection aid include product currently sell history loss expect operate loss foreseeable future profitable profitable fullyear operating basis profitable operating basis december accumulate deficit approximately million loss result principally expense associate research development program less extent sale general administrative expense product sale royalty revenue derive sale ambisome viread vistide daunoxome royalty arrangement relate tamiflu ambisome vistide develop drug treat hiv infection aid relate condition change regulatory commercial environment hiv infection aid therapy harm business product product development address hiv infection aid relate condition product include viread hiv infection aid vistide cmv retinitis daunoxome hivassociate kaposi sarcoma develop product base current policy current marketplace hiv infection aid therapie prediction future policy future marketplace therapie business subject substantial risk policy market change quickly unpredictably way impair ability obtain regulatory approval commercial acceptance product operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis achieve continued compliance delay commercialization product product develop sell approve subject extensive regulation fda comparable agency country continue clinical trial ambisome viread currently approve additional use conduct clinical trial adefovir dipivoxil anticipate conduct variety clinical trial file marketing approval additional product year corporate partner cubist pharmaceutical conduct clinical trial cidecin conduct clinical trial cidecin future product fail receive marketing approval timely basis failure cidecin meet primary endpoint cubist pharmaceutical pivotal phase iiiclinical trial cidecin treatment communityacquire pneumonia cause grampositive bacteria reevaluate regulatory strategy cidecin expect file marketing approval application cidecin certain adefovir dipivoxil cidecin approve fda european union regulatory authority country adefovir dipivoxil cidecin receive marketing approval place limitation use failure delay limitation regulatory change action recall delay commercialization product adversely affect result operation addition product market product manufacturer subject continual review later discovery previously unknown problem product manufacture production thirdparty manufacturer result restriction product manufacture product include withdrawal product market fail comply applicable regulatory requirement subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution result clinical trial approval product uncertain delay prohibit sell product number potential product reach development stage potential product include adefovir dipivoxil cidecin require demonstrate safety effectiveness product develop intend use extensive preclinical study clinical trial order obtain regulatory approval product result preclinical early clinical study accurately predict result later largescale clinical trial reason include preliminary result indicative effectiveness clinical trial achieve desire result clinical trial reveal unduly harmful effect drug effective drug delivery system desire indication successfully complete largescale clinical trial result marketable product reason include potential product show safe effective regulatory authority disagree result design study trial potential product difficult develop commercially viable product january cubist pharmaceutical announce pivotal phase iii clinical trial cidecin treatment communityacquire pneumonia cause grampositive bacteria cidecin successful meeting primary endpoint november fda advisory committee recommend approval application approve dose adefovir dipivoxil treat hiv infection kidney toxicity associate dose desire additional datum major concern committee follow recommendation inform fda approve application obtain additional datum satisfied concern raise committee base discussion terminate development adefovir dipivoxil treatment aid dose adefovir dipivoxil phase iii clinical trial adefovir dipivoxil hbv infection seek regulatory approval dose clinical result date indicate low dose result kidney toxicity experience adefovir dipivoxil effective treat hbv infection low dose certain low dose safe sufficient treatment benefit receive fda approval viread class drug adefovir dipivoxil observe kidney toxicity clinical trial viread kidney toxicity clinical trial adefovir dipivoxil hiv infection arise later stage clinical trial certain similar toxicity issue arise later ongoing clinical trial viread number company industry suffer similar setback advanced clinical trial despite promise result early trial end unable develop additional marketable product delay enrol patient develop suitable protocol clinical trial increase cost delay regulatory approval rate completion clinical trial depend rate patient enrollment substantial competition enroll patient clinical trial drug development competition delay clinical trial past addition recent improvement exist drug therapy particularly hiv hbv infection difficult enroll patient clinical trial patient population choose enroll clinical trial sponsor company choose alternative therapy delay plan patient enrollment result increase development cost delay regulatory approval clinical trial carry protocol acceptable regulatory authority committee responsible clinical study site study conduct delay prepare protocol receive approval delay start finish clinical trial addition feedback regulatory authority result early stage clinical study require modification delay later stage clinical trial type delay result increase development cost delay regulatory approval product development effort yield marketable product result study trial failure achieve regulatory approval market acceptance proprietary right manufacture issue success depend ability successfully develop obtain regulatory approval market new pharmaceutical product significant portion research conduct involve new unproven technology development product require substantial technical financial human resource product successfully complete potential product appear promise stage development fail reach market number reason include lack sufficient treatment benefit unacceptable toxicity preclinical study clinical trial failure receive necessary regulatory approval existence proprietary right party inability develop manufacturing method efficient costeffective capable meeting stringent regulatory standard product sale occur outside currency fluctuation impair financial result significant majority sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar return sale negatively impact financial condition hedge respect foreign account receivable past hedge exposure impact fluctuate foreign exchange rate forecast sale effective january begin use forward contract hedge percentage forecast international sale primarily sale denominate euro currency expect use forward contract reduce impact foreign currency fluctuation future result product development expense cause operating expense fluctuate quarter quarter clinical trial require regulatory approval product extremely expensive difficult accurately predict control timing expense quarter quarter uneven unexpected spending program cause operating result fluctuate quarter quarter depend relationship company research fund clinical development sale marketing performance revenue failure maintain relationship negatively impact business rely number significant collaborative relationship major pharmaceutical company research fund clinical development andor sale marketing performance include collaboration fujisawa healthcare glaxosmithkline hoffmannla roche pharmacia corporation eyetech pharmaceuticals inc sumitomo pharmaceuticals inc certain country rely international distributor sale ambisome country intend rely international distributor sale viread addition collaboration agreement cubist pharmaceuticals inc commercialize cubist antibacterial drug cidecin european country follow regulatory approval cubist responsible ongoing clinical development cidecin accordingly control rely cubist clinical trial regulatory filing cidecin cidecin meet primary end point cubist phase iii clinical trial communityacquire pneumonia cause grampositive bacteria expect file marketing approval application european union complicated skin soft tissue infection indication cidecin achieve success phase iii clinical trial ongoing clinical trial support regulatory approval cubist require conduct additional clinical trial choose conduct trial expense reliance collaborative relationship pose number risk include able control corporate partner devote sufficient resource program product dispute arise future respect ownership right technology develop corporate partner disagreement corporate partner lead delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose devote few resource marketing product product development distributor corporate partner unable pay give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue exist product include tamiflu ambisome decline january hoffmannla roche announce production problem liquid suspension form tamiflu approve treatment child young year old available expect available flu season production issue affect availability tablet form tamiflu adult adolescent year old expect current production issue material effect earning right market ambisome canada limited agreement fujisawa failure fujisawa effectively market ambisome reduce revenue right market ambisome canada subject agreement fujisawa term agreement sole marketing right ambisome country canada pay royalty connection sale significant asian market include japan copromote ambisome fujisawa manufacture ambisome sale canada sell ambisome fujisawa cost cost plus specify percentage canada fujisawa collect revenue ambisome sale pay approximately net sale success ambisome dependent primarily effort fujisawa canada success ambisome depend entirely fujisawa fujisawa fail effort potential revenue sale ambisome substantially reducedfailure hoffmannla roche effectively market tamiflu reduce potential revenue hoffmannla roche sole responsibility promote sell tamiflu worldwide basis control activity rely effort hoffmannla roche revenue receive sale tamiflu hoffmannla roche dedicate sufficient resource promotion tamiflu hoffmannla roche fail marketing effort royalty receive sale tamiflu decrease adversely affect inability establish future successful collaborative relationship impair financial result seek future collaborative relationship corporate partner fund research development expense develop commercialize potential product anticipate revenue collaborative agreement continue affect exist agreement time drug development program corporate partner able negotiate acceptable collaborative arrangement future arrangement negotiate successful fail establish additional collaborative relationship require undertake research development marketing manufacturing propose product expense discontinue reduce activity exist product product development accept physician insurer patient adefovir dipivoxil cidecin approve marketing establish market ability product achieve sustain market acceptance depend receipt scope regulatory approval government authority manage care organization adequately reimburse patient use product addition need convince medical patient advocacy community effectiveness product treat disease safety product administer patient advantage product competitive product physician patient patient advocate payor medical community general accept use product develop product accept result operation suffer company target disease condition competitive product company significantly reduce market acceptance product product development program target number disease condition include viral infection fungal infection bacterial infection commercially available product disease certain product wellestablishe therapy generate substantial sale addition large number company institution conduct wellfunde research development activity direct develop treatment disease product currently market development competitor technology product obsolete noncompetitive expect competition treatment disease increase future new product enter market advanced technology available compete license acquire technology company competitor potential competitor substantially great resource resource include superior product development capabilitie financial scientific manufacturing marketing managerial human resource competitor achieve superior patent protection obtain key technology receive regulatory approval achieve product commercialization early significantly great resource marketing organization large pharmaceutical company hinder ability compete successfully product compete product develop likely compete product company currently extensive wellfunde marketing sale operation company capable devote significantly great resource marketing effort marketing sale effort compete successfully effort company exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental party payor reimbursement cost product relate treatment government health administration authority private health insurer organization generally provide reimbursement government authority thirdparty payor increasingly challenge price medical product service particularly innovative new product therapy result low average sale price example majority sale ambisome vistide daunoxome subject reimbursement government agency result significant discount list price rebate obligation business adversely affect increase international pricing pressure pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general recent year new legislation propose federal state level effect major change health care system nationally state level proposal include prescription drug benefit proposal medicare beneficiary introduce congress federal reform legislation state enact health care reform legislation federal state development possible predict exact nature legislative health care reform result operation adversely affect reform europe success tamiflu approve sale viread depend largely obtain government reimbursement europe european country include united kingdom france patient reluctant pay prescription drug pocket expect success product development particularly europe depend ability obtain reimbursement reimbursement available reimbursement policy adversely affect ability sell product profitable basis addition international market government control price prescription pharmaceutical market marketing approval receivedin addition international market government control price prescription pharmaceutical market marketing approval receive pricing negotiation month long product sale attempt gain market share introductory pricing program competitor require low price country adversely affect result operation able obtain effective patent protect technology use competitor patent company require stop pay use require technology success depend significant degree ability obtain patent license patent right preserve trade secret operate infringe proprietary right right foreign issue patent file continue file patent application abroad relate technology risk patent issue application patent sufficient protect technology patent application confidential period time patent issue result know competitor file patent application technology cover pende application certain invent technology subject patent application cidecin protect method use patent generally provide level protection composition matter patent competitor file patent application receive patent obtain additional patent proprietary right block compete patent patent filing cover form adefovir dipivoxil china certain asian country application pende asian country include china relate form formulation adefovir dipivoxil asia major market hbv therapie potential indication adefovir dipivoxil obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale commercial value product limit addition patent provide adequate protection certain country africa asia include china competitor file patent application cover technology participate interference proceeding litigation determine right patent litigation interference proceeding expensive successful success depend large ability operate infringe patent proprietary right party infringe patent prevent commercialize product require obtain license party certain able obtain alternative technology require license obtain technology license certain term reasonable fail obtain license alternative technology unable develop product example decide use assay method drug screening program ict pharmaceutical patent cover part program ict pharmaceutical offer nonexclusive license patent industrywide licensing program determine need patent program need obtain license develop acquire alternative technology program certain able obtain license reasonable term alternative technology serve need future drug development addition use significant proprietary technology rely unpatented trade secret proprietary knowhow protect certain aspect production technology trade secret know independently discover competitor number develop country government official group suggest pharmaceutical company drug hiv infection available low cost case governmental authority indicate pharmaceutical company patent enforceable prevent generic competition major pharmaceutical company greatly reduce price hiv drug certain develop country certain country permit enforcement patent sale viread country reduce generic competition alternatively government country require grant compulsory license allow competitor manufacture sell version viread country reduce viread sale respond governmental concern reduce price viread case result operation adversely affect manufacturing problem delay product shipment regulatory approval vistide adefovir dipivoxil viread rely party manufacture bulk drug substance final drug product clinical commercial purpose hoffmannla roche responsible manufacturing tamiflu encounter problem process revenue sale tamiflu decrease depend party perform obligation effectively timely basis party fail perform require clinical trial submission product regulatory approval delay delay impair ability deliver commercial product timely basis impair competitive position hoffmannla roche announce production problem liquid suspension form tamiflu approve treatment child young year old currently available expect available flu season expect current production issue material effect earning manufacture ambisome daunoxome facility san dimas california formulation manufacturing facility san dimas california manufacturing facility ireland perform certain quality control testing labeling packaging use party alternate contract supplier fill freeze dry certain batch product event natural disaster include earthquake equipment failure strike difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome daunoxome meet market need able obtain material necessary manufacture product material utilize operation facility example depend single supplier high quality amphotericin daunorubicin hcl distearoylphosphatidylcholine high quality cholesterol manufacture liposomal product supplier key component material name new drug application file fda product significant delay occur qualification new supplier require supply supplier interrupt reason unable ship ambisome viread vistide daunoxome supply product development clinical trial limited experience manufacturing product able develop adequate manufacturing capacity potential product need develop production technology use large scale order conduct clinical trial produce product commercial sale acceptable cost certain able implement development successfully manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation fda current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard addition manufacturing operation subject routine inspection regulatory agency similar regulation effect country business rise product liability claim cover insurance indemnity agreement testing manufacturing marketing use ambisome viread vistide daunoxome product development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company successful product liability claim require pay substantial amount impair financial condition ability clinically test market product additionally require governmental regulation test product sell patient result test require determine recall product market subsequent testing product recall increase potential exposure product liability claim internal research program effort obtain right new product party yield potential product clinical development long term success depend ability identify internal research program potential product candidate develop new pharmaceutical product obtain new product product candidate license party significant portion research conduct involve new unproven technology research program identify product candidate require substantial technical financial human resource candidate identify research program appear promise route identify potential product candidate fail yield product candidate clinical development number reason include research methodology successful identify potential product candidate potential product candidate study show unduly harmful effect characteristic indicate unlikely effective drug unable develop large scale manufacturing method efficient costeffective capable meeting stringent regulatory standard hold intellectual property right prevent develop make sell certain product unable obtain suitable product candidate product party number reason include unable purchase license compound term allow appropriate return product competitor unwilling assign license product right unable identify suitable product product candidate area expertise product candidate acquire approve regulatory authority problem safety effectiveness unable develop suitable potential product candidate internal research program obtain right new product party future revenue growth suffer use hazardous material chemical viruse radioactive compound expose potential liability research development involve control use hazardous material chemical viruse radioactive compound believe safety procedure handle dispose material comply standard prescribe state federal regulation completely eliminate risk accidental contamination injury material event accident hold liable significant damage fine item property corporate headquarters include principal executive office certain research facility locate foster city california location lease approximately square foot space proximately locate building sublease cover approximately square foot space group building expire december renewal option remain lease expire march september option renew lease additional fiveyear period occupy facility san dimas california location lease approximately square foot space house research development activity manufacture certain administrative function lease expire november fiveyear renewal option addition lease adjacent warehouse facility square foot space use product distribution administrative function lease expire april additional fiveyear extension addition lease approximately square foot space sale market regulatory finance information technology human resource operation europe australia include prepaid year lease square foot manufacturing distribution facility ireland lease expiration date believe facility adequate suitable current nearterm future needsitem legal proceeding august enter settlement elan corporation successor liposome company inc agree dismiss legal proceeding involve patent relate liposomal formulation amphotericin settlement agreement elan agree sue connection worldwide production sale ambisome give right use patent term settlement agreement require payment base ambisome sale year party legal action arise ordinary course business believe legal action significant impact business item submission matter vote security holder item market registrant common stock relate stockholder matter common stock trade nasdaq stock market symbol gild follow table set forth period indicate high low intraday sale price share common stock nasdaq stock market price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low quarter second quarter quarter fourth quarter quarter second quarter quarter fourth quarter february march company implement twoforone stock split form stock dividend share share amount period present restate reflect split february share common stock outstanding hold approximately stockholder record pay cash dividend common stock inception anticipate pay foreseeable future item select financial datum gilead sciences inc select consolidated financial datum thousand share datum year end december consolidated statement operation datum total revenue total cost expense loss operation incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net incomeloss amount common sharebasic incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net incomeloss sharebasic share share calculationbasic amount common sharedilute incomeloss cumulative effect change accounting principle cumulative effect change accounting principle net incomeloss sharedilute share share calculationdilute december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation convertible subordinated debt accumulate deficit total stockholder equity complete sale oncology asset relate technology osi record nonoperating gain million record nonoperate gain million sale percent interest proligo period prior year end december restate reflect merger nexstar pharmaceuticals inc july account pool interest gilead adopt statement financial accounting standard nos collectively refer sfas accounting derivative instrument hedge activity quarter change account change accounting principle effective quarter gilead adopt sec staff accounting bulletin sab revenue recognition financial statement change account change accounting principle february march company implement twoforone stock split form stock dividend share share amount period present restate reflect split cash dividend declare pay company common stock item management discussion analysis financial condition result operation overview gilead incorporate delaware june independent biopharmaceutical company focus discovery development commercialization antiviral antibacterial antifungal treat lifethreatene infectious disease multinational company revenue approve product marketing operation country currently market viread tenofovir disoproxil fumarate treatment hiv infection ambisome amphotericin liposome injection antifungal agent daunoxome daunorubicin citrate liposome injection drug approve treatment kaposi sarcoma vistide cidofovir injection treatment cytomegalovirus cmv retinitis hoffmannla roche inc market tamiflu oseltamivir phosphate treatment influenza collaborative agreement gilead seek add exist portfolio product clinical development program internal discovery program active product acquisition inlicense strategy internal discovery activity include identification new molecular target target screen medicinal chemistry addition currently develop product treat hepatitis virus bacterial infection expertise liposomal drug delivery technology use develop drug safe easy patient tolerate effective december complete sale oncology asset osi pharmaceuticals inc transaction value million cash osi stock transaction allow focus continue strengthen core expertise infectious disease note consolidated financial statement information february march gilead complete twoforone stock split effect form stock dividend stockholder record february february respectively accordingly share share amount period present restate reflect split year end december gilead adopt statement financial accounting standard nos collectively refer sfas accounting derivative instrument hedging activity result cumulative effect change accounting principle year end december gilead adopt securities exchange commission staff accounting bulletin revenue recognition financial statement result cumulative effect change accounting principle july gilead enter business combination nexstar pharmaceuticals inc nexstar business combination account pool interest historical consolidated financial statement gilead period prior business combination restate include financial position result operation cash flow nexstar certain prior period amount reclassify conform current presentationforwardlooking statement risk factor follow discussion contain forwardlooke statement involve risk uncertainty gilead actual result differ materially discuss forwardlooke statement factor cause contribute difference include limited discuss section caption business include risk factor forwardlooke statement include document base information currently available gilead assume obligation update forwardlooke statement follow discussion read conjunction consolidated financial statement note include report ambisome sale rely sale ambisome significant portion operating income lower price product compete ambisome product recently approve compete ambisome product fda deem approvable product develop compete ambisome future product achieve market acceptance product development commercially available revenue sale ambisome likely decrease result reduction operating income viread sale future expect rely sale viread portion operate income number drug treat hiv infection aid currently sell advanced stage clinical development include product currently sell company significant competitor hivaid market glaxosmithkline bristolmyers squibb hoffmannla roche pfizer merck boehringeringelheim abbott laboratories give broad range competitor depth resource early determine viread achieve significant market penetration particularly use treatment nave patient give datum support viread approval treatment experience patient population market acceptance product ability product achieve sustain market acceptance depend number factor include receipt scope regulatory approval availability public private insurance reimbursement product safety efficacy tolerability cost product product compare competitive product product achieve sustain market acceptance result operation suffer tamiflu new class drug represent new approach treat prevent flu order tamiflu achieve market acceptance marketing partner roche change attitude treatment prevention influenza regulatory process food drug administration foreign agency reject limit commercialization product number reason include disagree result design clinical trial believe product unacceptable efficacy toxicity tolerability believe product safely efficiently manufacture commercial basis agency reject limit commercialization product financial result adversely affect clinical trial require regulatory approval product extremely expensive difficult accurately predict control timing expense quarter quarter addition regulatory agency require conduct additional unanticipated clinical trial product cost substantial medicaid governmental reimbursement discount program business adversely affect increase pricing pressure abroad pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general enact legislation require pay set rebate offer discount product reimburse medicaid purchase outpatient medicine certain public health service entity certain hospital sell certain federal purchaser include veteran administration recent year new legislation propose federal state level effect major change health care system nationally state level proposal include prescription drug benefit proposal medicare beneficiary introduce congress federal reform legislation state enact health care reform legislation federal state development possible predict exact nature legislative health care reform result operation adversely affect national state government require sell market product low price compulsory license generic competition number develop country government official group suggest pharmaceutical company drug hiv infection available low cost case governmental authority indicate pharmaceutical company patent enforceable prevent generic competition major pharmaceutical company greatly reduce price hiv drug certain develop country certain country permit enforcement patent sale viread country reduce generic competition alternatively government country require grant compulsory license allow competitor manufacture sell version viread country reduce viread sale respond governmental concern reduce price viread case result operation adversely affect collaboration depend collaboration development commercialization certain product revenue include collaboration fujisawa sale ambisome united states canada collaboration roche sale tamiflu worldwide collaboration cubist clinical development cidecin collaboration fail number reason include partner devote sufficient resource development commercialization marketing product dispute arise partner seek additional collaboration collaboration fail unable establish additional collaboration financial result adversely affect foreign currency fluctuation significant majority product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar return sale negatively impact financial condition past hedge exposure impact fluctuate foreign exchange rate forecast sale effective january begin use forward contract hedge percentage forecast international sale primarily denominate euro currency hedge account receivable balance denominate foreign currency minimize eliminate exposure currency fluctuation date sale record date cash collect additionally mitigate impact currency rate fluctuation cash outflow certain foreign currency denominate raw material purchase enter foreign exchange forward contract hedge foreign currencydenominate account payable uncertain financial result expect financial result continue fluctuate quarter quarter fluctuation substantial fluctuation cause factor control include risk factor list profitable fullyear operating basis achieve sustain operating profitability december accumulate deficit million critical accounting policy estimatesgilead discussion analysis financial condition result operation base consolidated financial statement prepare accordance accounting principle generally accept united states preparation financial statement require estimate judgment affect report amount asset liability revenue expense relate disclosure asset liability ongoing basis evaluate estimate include related revenue recognition bad debt inventory accrue clinical preclinical expense contingency base estimate historical experience market specific assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ estimate different assumption condition gilead believe follow critical accounting policy affect significant judgment estimate preparation consolidated financial statement record estimate reduction revenue expect return expire product medicaid reimbursement customer incentive cash discount prompt payment expect return market drug generally low shelf life product range month viread month ambisome condition competitive market serve drug circumstance change action increase product return estimate offer customer incentive action result incremental reduction future revenue time return estimate change incentive offer maintain allowance doubtful account estimate loss result inability customer require payment financial condition customer deteriorate result impairment ability payment additional allowance require write inventory base quality control review individual raw material batch generally maintain inventory reserve base estimate obsolescence risk competition primarily shelf life product long current assumption future demand competition change actual market condition favorable project management additional inventory writedown require record accrual estimate clinical preclinical study cost cost significant component research development expense management accrue cost clinical study perform contract research organization base estimate work upfront cost remain activity generally straightline basis life individual contract study estimate match actual service perform organization determine patient enrollment level relate activity monitor patient enrollment level relate activity extent possible management underestimate activity level associate study give point time record significant research development expense future period result operation revenue total revenue million year million year million year include total revenue net product sale royalty income contract revenue include revenue research development collaboration net product sale revenue million compare million million revenue primarily derive sale ambisome represent total product sale total product sale total product sale report sale ambisome million increase ambisome sale million exclude impact decline foreign currency relative dollar sale ambisome increase significant majority gilead product sale denominate foreign currency past hedge exposure impact fluctuate foreign exchange rate forecast sale effective january begin use forward contract hedge percentage forecast international sale primarily denominate euro currency hedge account receivable balance denominate foreign currency reduce exposure currency fluctuation date sale record date cash collect sale ambisome million exclude impact decline foreign currency relative dollar sale ambisome increase versus report sale expect increase competition expect ambisome sale remain relatively flat versus report level assume foreign currency exchange rate remain consistent level compare recognize million viread sale represent total product sale sale daunoxome vistide million million respectively gilead recognize product sale revenue million sale daunoxome million sale vistide daunoxome sale million vistide sale million expect viread sale increase great percentage total revenue predict certainty actual viread sale record royalty revenue million compare million million threeyear period significant source royalty revenue sale ambisome united states fujisawa copromotion arrangement gilead fourth quarter begin recognize royalty revenues fujisawa sale ambisome month follow related product sale occur prior fourth quarter recognize royalty revenue month sale occur royalty revenue fujisawa million compare million million represent royalty month fujisawa sale ambisome record royalty revenue million million relate sale tamiflu tamiflu orally administer compound develop treat prevent viral influenza human gilead codevelope tamiflu hoffmannla roche ltd hoffmannla roche inc collectively roche roche own worldwide commercial right tamiflu require pay gilead royalty net sale product october fda approve tamiflu treatment influenza adult roche begin sell product commercially record royalty revenue roche quarter follow quarter relate tamiflu sale occur accordingly gilead begin recognize royalty tamiflu quarter significant decline royalty revenue attribute significantly low incidence flu season result product return roche expect tamiflu royalty increase somewhat result broad market penetration second half tamiflu approve prevention adult treatment influenza child approve japan treatment influenza adult february roche file european regulatory approval tamiflu treatment influenza adult child prevention adolescent adult unclear approval grantedsubstantially remain net royalty revenue recognize represent royalty sale vistide pharmacia pharmacia outside united states future period royalty sale vistide expect relatively flat decline slightly december securities exchange commission issue staff accounting bulletin sab revenue recognition financial statement thing sab describe sec staff position recognition certain nonrefundable upfront fee receive connection collaboration agreement previously recognize nonrefundable technology access fee receive connection collaboration agreement revenue receive collectibility probable technology transfer effective january change method accounting fee recognize related manufacturing obligation fulfil straightline basis term relate research development collaboration manufacturing supply arrangement appropriate method good match effort provide believe change accounting principle preferable base guidance provide sab cumulative effect change accounting principle record fourth quarter retroactively effective january defer revenue recognize contract revenue remain term research development manufacturing supply arrangement appropriate year end december impact cumulative change accounting principle increase net loss million recognize additional contract revenue million million accordance sab relate fee receive prior year million recognize relate collaborative relationship million relate initial licensing fee sumitomo million relate initial license fee pharmacia million recognize relate collaborative arrangement million sumitomo million pharmacia million relate initial licensing fee roche remain million sab relate defer revenue december result sumitomo pharmacia collaboration expect recognize contract revenue year remain defer revenue relate roche initial license fee december total contract revenue million compare million million primary source contract revenue licensing selex process patent estate archemix provide million contract revenue source contract revenue include million milestone payment roche relate development tamiflu collaboration agreement gilead roche million recognize work associate marketing agreement single significant source contract revenue milestone payment roche collaboration agreement record contract revenue roche million million million contract revenue roche include million milestone payment relate roche complete regulatory filing approval tamiflu japan million expense reimbursement million result adoption sab discuss include million milestone payment million reimbursement reimbursement roche decrease compare reimbursement similarly decrease relative tamiflu development effort ramp roche commercialization activity increase december gilead entitle additional milestone payment million roche achieve certain developmental regulatory milestone earn milestone payment roche agreement expect expense reimbursement roche agreement minimal reimbursement approximate actual relate cost incur october enter agreement archemix corporation relate selex technology agreement give archemix exclusive right selex process include therapeutic commercial application extent license preexist agreement archemix pay million require pay million require license agreement university technology corporation pay million payment pay million payment university technology corporation receive warrant purchase share archemix common stock value material require license agreement university technology corporation transfer warrant university technology corporation march enter agreement eyetech pharmaceuticals inc relate gilead proprietary aptamer eye know currently early clinical trial eye inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease term agreement eyetech receive worldwide right therapeutic use eye product successfully commercialize eyetech pay royalty worldwide sale product eyetech responsible research development cost provide clinical supply product eyetech march receive million upfront licensing fee eyetech april recognize revenue ratably oneyear supply agreement period accordingly million license fee record contract revenue remainder recognize revenue quarter entitle additional cash payment eyetech million eyetech reach certain eye development milestone additionally receive warrant purchase share eyetech series convertible prefer stock exercisable price share price stock issue investor november gilead somalogic inc enter agreement gilead assign somalogic sole exclusive license certain intellectual property include patent patent application term agreement somalogic require pay gilead total million nonrefundable installment second installment total million receive november record contract revenue receipt installment million receive recognize contract revenue november cost expense cost good sell million compare million million percentage net product sale cost good sell connection european product sale price product currency country product sell payment currency significant majority manufacturing cost dollar decline value payment currency relative dollar negatively impact gross margin manufacturing cost remain approximately revenue report dollar decline gross margin negatively impact factor discuss product sale section caption revenue exclude impact foreign exchange rate report sale revenue cost sale percentage net product sale approximately consistent level cost sale percentage annual basis range recent year potential impact unpredictable uncontrollable change payment currency relative dollar expect cost good sell percentage net product sale remain materially consistent rate future year change nature mix product sale recent commercial launch viread hiv infection impact relationshipin research development expense exceed total cost expense expense represent approximately total cost expense major component expense consist personnel cost include salary benefit clinical study perform contract research organization material supply overhead allocation consist support facility relate cost research development activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology work clinical development cost include phase iii clinical trial expand access program pharmaceutical development cost consist product formulation chemical analysis spend approximately million research million clinical development million pharmaceutical development activity compare spend approximately million research million clinical development million pharmaceutical development activity spending consist million research million clinical development million pharmaceutical development activity total expense million compare million million million increase spending versus attributable recognition million million upfront payment million clinical milestone payment cubist european licensing agreement cidecin addition expense associate phase iii clinical trial expand access program viread hiv infection phase iii clinical program adefovir dipivoxil hbv infection increase approximately million million respectively year base current budget program expect expense approximately million million low reflect sale oncology asset osi december decrease level activity associate european expand access program viread result expect decrease spending percentage total cost expense expect spending level increase level major development project include viread adefovir dipivoxil hbv infection incur increase cost program phase iii clinical trial additionally upfront payment fourth quarter license oncology product glaxo smith kline southern research institute right subsequently assign osi sale oncology asset december increase offset significantly low expense development adefovir dipivoxil hiv infection program discontinue fourth quarter additionally reduce workforce boulder employee complete merger nexstar recent industry report indicate biopharmaceutical product generally take year average year research develop bring market new prescription medicine average generally consistent project develop internally recent product development timeline accelerate basis drug development process include step define fda process begin file initial drug application ind successful allow opportunity clinical study potential new medicine clinical development typically involve phase study phase iii generally account average seven year drug total development time significant cost associate clinical development phase iii trial tend long large study conduct drug development process currently product development phase iii study successful development product highly uncertain estimation completion date expense vary significantly product difficult predict complete discussion risk uncertainty associate complete development product risk factor section item sell general administrative sga expense million compare million million increase expense versus primarily gilead increase global marketing effort expansion sale force support commercial launch viread hiv infection expect sga expense approximately million million high level primarily increase marketing activity associate launch viread european union preparation commercial launch adefovir dipivoxil hbv infection major factor contribute decrease sga expense level inclusion million mergerrelate expense mergerrelate expense primarily consist transaction cost include professional fee filing fee print cost employee severance cost writedown certain nexstar property equipment expect future operation total employee severance cost million relate termination employee majority boulder colorado facility exclude merger expense sga expense essentially flat compare high general administrative expense offset saving sale marketing expense increase spending include cost implement new upgrade information technology system legal cost incur connection new collaboration agreement corporate project sale marketing expense reflect cost saving elimination second half duplicate position function combine gilead nexstar organization sale marketing expense include cost expand sale marketing capacity anticipation thenplanne commercial launch adefovir dipivoxil hiv infection discontinue fourth quarter litigation settlement relate expense incur litigation settlement relate expense million million million reach settlement elan corporation plc elan successor company liposome company company agree dismiss legal proceeding involve ambisome gilead liposomal formulation amphotericin term settlement agreement initial payment elan million require additional payment base ambisome sale payment subject certain minimum maximum amount million accounting charge record represent net present value future minimum payment require record expense quarter base difference future minimum payment previously accrue amount significant expect difference future minimum maximum payment elan material gain sale oncology asset december complete sale oncology asset pipeline clinical stage oncology product relate intellectual property boulder colorado operation include clinical research drug development personnel infrastructure facility osi pipeline clinical candidate include liposomal lurtotecan nucleoside analogue liposomal thymidylate synthase inhibitor closing date receive million cash osi common stock value approximately million company record nonoperate gain million fourth quarter result transaction addition record income taxis million connection transaction gain sale unconsolidate affiliatein august sell percent interest proligo llc proligo degussa corporation million cash proligo joint venture gilead skw americas inc focus manufacturing oligonucleotide skw americas subsidiary degussa corporation hold remain percent proligo proceed net gilead investment proligo reflect million gain sale unconsolidated affiliate interest income interest expense record interest income million compare million million increase high average balance invest fund december receive approximately million issuance convertible subordinate note net debt issuance cost increase high interest rate investment portfolio expect interest income materially consistent level receipt million cash sale oncology asset december offset low interest rate portfolio fix income security incur interest expense million compare million million significant increase year interest million convertible subordinate note interest expense consist primarily interest million convertible note convert common stock august decrease level occur primarily august debt conversion interest expense include year interest million convertible note expect interest expense remain consistent expense level incur year expense million convertible subordinate note income taxis provision income taxis million million million respectively period record income tax expense associate income foreign subsidiary significant increase income tax expense result principally gain sale oncology asset osi record approximately million federal state alternative minimum taxis equity loss unconsolidated affiliate record million equity loss unconsolidated affiliate proligo prior date sale percent interest record million equity loss proligo represent percent share proligo loss thirteenmonth period end december fourth quarter proligo change fiscal yearend december november record million equity loss proligo fiscal year end november cumulative effect change accounting principle year end december gilead adopt sfas accounting derivative instrument hedging activity result cumulative effect change accounting principle million year end december gilead adopt securities exchange commission staff accounting bulletin revenue recognition financial statement result cumulative effect change accounting principle million note consolidated financial statement discussion liquidity capital resource cash cash equivalent marketable security total million december million december increase million primarily million cash million osi common stock receive sale oncology asset osi december major source use cash include proceed issuance stock employee stock plan million proceed million sale interest proligo offset capital expenditure million cash fund operating activity account receivable balance december million compare million december growth primarily yearoveryear increase net product sale ambisome initial sale viread certain country payment typically slow primarily greece spain portugal italy account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding december past account receivable greece spain portugal italy total approximately million approximately million day past december past receivables country million approximately million day past date experience modest loss respect collection account receivable believe past account receivable include customer country collectible continually seek improve collection process ensure fully collect amount base product sale collection timely significant change working capital include million increase inventory addition account payable increase million result increase raw material purchase increase use contract manufacturer substantially growth inventory account payable support recent european launch viread change work capital include increase accrue liability million accrue clinical preclinical expense increase million primarily advanced accelerate phase iii clinical trial adefovir dipivoxil hbv infection accrue compensation increase million december million december principally expansion sale force support viread launch accrue liability increase million consist principally transaction cost income taxis payable arise sale oncology asset osi noncurrent asset decrease million million december million december decrease sale percent interest proligo investment proligo december approximately million approximately million date sale decrease partially offset increase result million unrecognized portion million license fee payment cubist million valuation warrant purchase stock eyetech recognize accordance sfa million balance result cubist payment include noncurrent asset december prior january gilead terminate right agreement respect preclinical oral formulation daptomycin develop cubist cubist discontinue development oral formulation gilead entitle receive refund cubist capital expenditure million million million expenditure primarily facility improvement accommodate growth laboratory manufacturing equipment million spend approximately research development relate expect capital spending decrease somewhat compare level percentage allocate research development remain consistent previous year august redeem convertible subordinated debenture cash price principal debenture outstanding plus accrued interest redemption price provide original debenture indenture redemption entire million principal debenture outstanding time convert newly issue share gilead common stock august defer debt issuance cost million relate debenture charge additional pay capital connection conversion debenture common stock december issue million convertible subordinated note december private offering note currently convertible total share gilead common stock share conversion price high common stock price note issuance date note redeemable option time december specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note april maintain million unsecured line credit bear interest float rate major financial institution term line credit require maintain certain financial ratio limitation ability incur additional debt engage certain significant transaction line credit include foreign exchange facility expire april renew foreign exchange facility april renew line credit require financial ratio limitation debt transaction foreign exchange facility special purpose entity unconsolidate financial statement involve nonexchange trade commodity contract account fair value commercial commitment relate party employee loan contractual obligation form litigation settlement capital operating lease note payable clinical research organization contract believe exist capital resource include fix income equity security supplement net product sale contract royalty revenue adequate satisfy capital need foreseeable future future capital requirement depend factor include commercial performance ambisome viread product development receive marketing approval progress research development effort scope result preclinical study clinical trial cost timing outcome regulatory review rate technological advance determination commercial potential product development administrative expense status competitive product establishment manufacturing capacity thirdparty manufacturing arrangement expansion sale marketing capability possible geographic expansion establishment additional collaborative relationship company future require additional funding form proceed equity debt financing additional collaborative agreement corporate partner fund require assure available favorable term recent accounting pronouncement july financial accounting standard board fasb issue statement financial accounting standard business combination sfas goodwill intangible asset sfas sfas eliminate poolingofinterest method accounting business combination qualify business combination initiate prior july sfas clarifie criterion recognize intangible asset separately goodwill requirement sfas effective business combination account purchase method complete june sfas goodwill indefinite live intangible asset long amortize review annually frequently impairment indicator arise impairment separable intangible asset deem indefinite life continue amortize useful life maximum life amortization provision sfas apply goodwill intangible asset acquire june account business combination purchase method accounting adoption sfas july material impact company financial position result operation adoption sfas january material impact company financial position result operation august fasb issue sfas accounting impairment disposal longlive asset sfas establish single accounting model asset dispose sale previously hold newly acquire sfas retain presentation discontinue operation income statement broaden presentation include component entity sfas effective fiscal year begin december interim period adoption sfas january material impact company financial position result operation market risk disclosuresforeign currency exchange risk operation include manufacture sale activity united states sale activity europe australia result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change exchange rate dollar foreign currency significant euro british pound australian dollar dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business mitigate impact change currency exchange rate cash flow foreign currency sale transaction enter foreign exchange forward contract hedge foreign currencydenominate account receivable additionally mitigate impact currency rate fluctuation cash outflow certain foreign currencydenominate raw material purchase enter foreign exchange forward contract hedge foreign currencydenominate account payable follow table summarize notional amount average currency exchange rate fair value open foreign exchange forward contract december contract maturity year exception hedge contract intend hedge raw material purchase quarter notional million insignificant fair value december maturity month average rate state term foreign currency dollar fair value represent estimate settlement amount december notional amount fair value thousand fair value currency notional average rate december australian dollar british pound danish krone euro norwegian krone swiss franc significant majority product sale denominate foreign currency increase value dollar foreign currency past reduce future reduce dollar return sale negatively impact financial condition past hedge exposure impact fluctuate foreign exchange rate forecast sale effective january begin use forward contract hedge percentage forecast international sale primarily denominate euro currency interest rate risk portfolio availableforsale investment security fixedrate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base maturity industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestbeare asset fixedrate liability december dollar thousand year end december fair value december total asset availableforsale security average interest rate liability minimum litigation settlement include current portion discount rate longterm obligation include current portion average interest rate convertible subordinated debenture interest rate longterm obligation consist capital lease operating lease net noncancelable sublease debt secure property plant equipment interest portion payment include item quantitative qualitative disclosure market risk quantitative qualitative disclosure market risk include caption market risk disclosure item item financial statement supplementary datum financial statement require item set forth begin report item change disagreement accountant account financial disclosure applicable iii item director executive officer registrant information require item concern director executive officer incorporate reference section definitive proxy statement file sec pursuant regulation connection annual meeting proxy statement heading nominee executive officer compliance section security exchange act item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee report item security ownership certain beneficial owner management information require item incorporate reference section proxy statement head security ownership certain beneficial owner management item certain relationship relate transaction information require item incorporate reference section proxy statement heading compensation committee interlock insider participation certain transaction executive compensation item exhibit financial statement schedule report form follow document file schedule include report schedule omit require require information include financial statement note thereto exhibit follow exhibit file herewith incorporate reference exhibit exhibit footnote number description document asset purchase agreement registrant osi pharmaceuticals inc date november amend restate certificate incorporation registrant amend bylaw registrant amend restate march reference exhibit exhibit amend restate right agreement date october registrant chasemellon shareholder services llc agreement plan merger date february registrant gazelle acquisition sub inc nexstar pharmaceuticals inc indenture date december registrant chase manhattan bank trust company national association include form note registration right agreement date december registrant morgan securities inc chase securities inc lehman brothers inc morgan stanley incorporate form indemnity agreement enter registrant director executive officer form employee proprietary information invention agreement enter registrant certain officer key employee registrant incentive stock option plan relate agreement registrant supplemental stock option plan relate agreement registrant employee stock purchase plan amend march registrant stock option plan amend restate april form nonqualified stock option issue certain executive officer director vintage park research development net lease registrant vintage park associate date march premise locate lakeside drive foster city california relate addendum exhibit amendment letter agreement date september registrant iocbrega exhibit certain confidential information omit vintage park research development net lease registrant vintage park associate date september premise locate lakeside drive foster city california related exhibit amendment agreement date october registrant iocbrega relate license agreement exhibit certain confidential information omit amendment agreement date december registrant iocbrega loan agreement date october registrant mark perry melanie pea registrant nonemployee director stock option plan amend january relate form stock option grant vintage park research development lease registrant wcb sixteen limited partnership date june premise locate lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limit partnership date june premise locate lakeside drive foster city california amendment vintage park research development lease registrant wcb seventeen limit partnership date june premise locate lakeside drive foster city california license supply agreement registrant pharmacia upjohn date august certain confidential information omit development license agreement registrant hoffmannla roche ltd hoffmannla roche inc date september certain confidential information omit amendment vintage park research development lease registrant spieker property date august premise locate lakeside drive foster city california nexstar pharmaceuticals inc incentive stock plan adopt february amend nexstar pharmaceuticals inc director option plan adopt july vestar inc stock option plan lease date march vestar inc majestic realty patrician associates inc amendment thereto amendment thereto date june amendment date january majestic realty patrician associates inc registrant lease date march vestar inc majestic realty patrician associates inc assignment royalty agreement date december effective june vestar inc city hope national medicalcenter license agreement effective august vestar inc regents university california agreement fujisawa usa inc vestar inc date august amendment thereto date amendment agreement fujisawa usa inc vestar inc date april fujisawa usa inc vestar inc certain confidential information omit amendment agreement fujisawa usa inc registrant date march agreement fujisawa usa inc vestar inc date august lease date april vestar inc majestic realty patrician associates inc amendment lease date april majestic realty patrician associates inc vestar inc amend lease date april majestic realty patrician associates inc vestar inc license distribution agreement date september sumitomo pharmaceutical ltd nexstar pharmaceuticals inc certain confidential information omit settlement agreement date august nexstar pharmaceuticals inc fujisawa usa inc liposome company inc certain confidential information omit amendment date april sumitomo pharmaceutical ltd nexstar pharmaceuticals inc license distribution agreement date september sumitomo nexstar pharmaceuticals inc corporate plan retirement select planbasic plan document corporate plan retirement select planadoption agreement addendum gilead sciences inc defer compensation plan subsidiary registrant consent ernst young llp independent auditor consent pricewaterhousecooper llp independent auditor power attorney reference signature file exhibit registrant annual report fiscal year end december incorporate reference file exhibit registrant quarterly report form quarter end december incorporate reference file exhibit nexstar pharmaceuticals inc quarterly report form quarter end june incorporate reference file exhibit registrant current report form file october incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit registrant annual report fiscal year end march incorporate referencefile exhibit registrant annual report fiscal year end march incorporate reference file exhibit registrant quarterly report form quarter end june incorporate reference file exhibit registrant quarterly report form quarter end september incorporate reference file exhibit registrant current report form file march incorporate reference file exhibit nexstar pharmaceuticals inc fiscal year end december incorporate reference file exhibit nexstar pharmaceuticals inc fiscal year end december incorporate reference file exhibit nexstar pharmaceuticals inc form quarterly period end september incorporate reference file exhibit nexstar pharmaceuticals inc fiscal year end december incorporate reference file march exhibit nexstar pharmaceuticals inc registration statement form file incorporate reference file exhibit nexstar pharmaceuticals inc form quarterly period end september incorporate reference file exhibit nexstar pharmaceuticals inc form quarter end june incorporate reference file exhibit registrant year end december incorporate reference file exhibit registrant year end december incorporate reference file exhibit registrant registration statement form amend incorporate reference file exhibit registrant year end december incorporate reference file exhibit registrant current report form file january incorporate reference report form registrant file report form fourth quarter january registrant file current report form relate completion sale oncology asset pipeline clinical stage oncology product relate intellectual property boulder colorado operation include clinical research drug development personnel infrastructure facility osi pharmaceuticals inc form include unaudited pro forma condense consolidated balance sheet september present transaction occur date unaudite pro forma condense consolidated statement operation year end december month end september present transaction occur january january respectively gilead sciences inc consolidated financial statement year end december content report independent auditor report independent accountant audit consolidated financial statement consolidate balance sheet consolidate statement operation consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement report ernst young llp independent auditor board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc subsidiary december relate consolidated statement operation stockholder equity cash flow year period end december audits include financial statement schedule list item annual report financial statement schedule responsibility management gilead sciences inc responsibility express opinion financial statement schedule base audits audit financial statement proligo llc limited liability company investment reflect accompany consolidated financial statement equity method accounting investment proligo llc represent consolidated total asset december net loss proligo llc respectively financial statement proligo llc audit auditor report furnish insofar opinion consolidated financial statement relate datum include proligo llc base solely report conduct audits accordance auditing standard generally accept united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits report auditor provide reasonable basis opinion opinion base audits report auditor consolidated financial statement refer present fairly material respect consolidate financial position gilead sciences inc subsidiary december consolidate result operation cash flow year period end december conformity accounting principle generally accept united states opinion financial statement schedule refer consider relation basic financial statement take present fairly material respect information set forth discuss note consolidated financial statement effective january company change method accounting derivative instrument hedge activity effective january change method accounting nonrefundable upfront fee receive connection collaboration agreement ernst young llp palo alto california january paragraph title stock split note date march report independent accountant board director member proligo llc opinion accompany consolidated balance sheet relate consolidated statement operation member equity cash flow present fairly material respect financial position proligo llc subsidiary december november result operation cash flow thirteenmonth end december year end november period august november respectively conformity accounting principle generally accept united states america financial statements responsibility company management responsibility express opinion financial statement base audit conduct audits statement accordance auditing standard generally accept united states america require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion pricewaterhousecooper llp broomfield colorado january gilead sciences inc consolidated balance sheet thousand share amount december asset current asset cash cash equivalent marketable security account receivable net allowance doubtful account inventory prepaid expense total current asset property plant equipment net noncurrent asset liabilitie stockholder equity current liability account payable accrue clinical preclinical expense accrue compensation employee benefit accrue liability defer revenue longterm obligation year total current liability longterm defer revenue accrue litigation settlement expense year longterm obligation year convertible subordinated debt commitment contingency accompany note stockholder equity prefer stock par value share issuable series share authorize outstanding common stock par value share share authorize share issue outstanding december share issue outstanding december additional paidin capital accumulate comprehensive income loss defer compensation accumulate deficit total stockholder equity accompany note gilead sciences inc consolidated statement operation thousand share amount year end december revenue product sale net royalty revenue net contract revenue contract revenuesab total revenue cost expense cost good sell research development sell general administrative total cost expense loss operation gain sale oncology asset gain sale unconsolidated affiliate interest income interest expense income loss provision income taxis equity loss unconsolidated affiliate cumulative effect change accounting principle provision income taxis equity loss unconsolidated affiliate income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss amount common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharebasic share share calculationbasic amount common sharedilute income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharedilute share share calculationdilute accompany note gilead sciences inc consolidated statement stockholder equity thousand accumulate common stock additional comprehensive total prefer paidin income defer accumulate stockholder stock share capital loss compensation deficit equity balance january net loss unrealize loss available forsale security net foreign currency translation adjustment comprehensive loss employee stock purchase plan option exercise net warrant exercise net conversion share prefer stock conversion convertible subordinate debenture amortization defer compensation compensatory stock transaction balance december net loss unrealize gain available forsale security net foreign currency translation adjustment comprehensive loss employee stock purchase plan option exercise net warrant exercise net conversion convertible subordinated debenture amortization defer compensation compensatory stock transaction balance december net income unrealize gain available forsale security net foreign currency translation adjustment unrealize gain cash flow hedge net comprehensive income employee stock purchase plan option exercise net tax benefit employee stock plan amortization defer compensation compensatory stock transaction balance december accompany note gilead sciences inc consolidated statement cash flow thousands year end december operating activity net income loss adjustment reconcile net income loss net cash operating activity depreciation amortization net effect change accounting principle compensation expense stock option transaction gain sale oncology asset net security receive gain sale unconsolidated affiliate equity loss unconsolidated affiliate litigation settlement charge net provision doubtful account tax benefit employee stock plan net unrealized gain loss foreign currency transaction change operate asset liability account receivable inventory prepaid expense asset longterm prepay royalty account payable accrue liability defer revenue exclude net effect change accounting principle net cash operating activity invest activity purchase marketable security sale marketable security maturity marketable security capital expenditure proceed sale oncology asset proceed sale unconsolidated affiliate investment unconsolidated affiliate net cash provide investing activity financing activity proceed issuance common stock repayment longterm debt proceed issuance convertible subordinate note net issuance cost net cash provide financing activity effect exchange rate change cash net increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental disclosure cash flow information interest pay income taxis pay noncash investing financing activity osi common stock receive sale oncology asset common stock issue conversion debenture reclassification defer debt issuance cost additional paidin capital conversion subordinate debenture accompany note gilead sciences inc note consolidated financial statement december organization summary significant accounting policy overview gilead incorporate delaware june independent biopharmaceutical company focus discovery development commercialization antiviral antibacterial antifungal treat lifethreatene infectious disease multinational company revenue approve product operation country currently market viread treatment hiv infection ambisome antifungal agent daunoxome drug approve treatment kaposi sarcoma vistide treatment cytomegalovirus cmv retinitis hoffmannla roche inc market tamiflu treatment influenza collaborative agreement gilead seeking add exist portfolio product clinical development program internal discovery program active product acquisition inlicense strategy internal discovery activity include identification new molecular target target screen medicinal chemistry addition currently develop product treat hepatitis virus bacterial infection expertise liposomal drug delivery technology use develop drug safe easy patient tolerate effective fully describe note july gilead enter business combination merger nexstar pharmaceuticals inc nexstar business combination account pool interest historical consolidated financial statement gilead year prior business combination restate include financial position result operation cash flow nexstar material adjustment necessary conform accounting policy company cost merger charge operation accompany consolidated financial statement include account company wholly majorityowne subsidiary significant intercompany transaction eliminate certain prior period amount reclassify consistent current presentation stock split february march gilead complete twoforone stock split effect form stock dividend stockholder record february february respectively accordingly share share amount period present restate reflect split change accounting principle gilead adopt statement financial accounting standard sfas nos collectively refer sfas accounting derivative instrument hedge activity quarter change account change accounting principle note derivative financial instrument effective quarter gilead adopt sec staff accounting bulletin sab revenue recognition financial statement change account change accounting principle note critical accounting policy estimate preparation financial statement require estimate judgment affect report amount asset liability revenue expense relate disclosure asset liability ongoing basis evaluate estimate include related revenue recognition bad debt inventory accrue clinical preclinical expense contingency base estimate historical experience market specific assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate different assumption condition revenue recognition product sale revenue recognize passage legal title inventory satisfaction company performance obligation company provide customer general right product return company accept return product expire deem damage defective deliver provision doubtful account estimate product return cash discount government discount rebate contract revenue research development record earn base performance requirement contract nonrefundable contract fee performance obligation exist continue involvement gilead recognize early payment receive collection assure revenue nonrefundable upfront license fee continue involvement development collaboration obligation supply product isrecognize manufacturing obligation fulfil ratably development period period manufacturing obligation appropriate revenue associate substantive performance milestone recognize base achievement milestone define respective agreement revenue research development cost reimbursement contract recognize related cost incur advance payment receive excess amount earn classified defer revenue royalty revenue sale ambisome recognize month follow correspond sale occur royalty revenue sale vistide tamiflu recognize receive quarter follow quarter correspond sale occur research development cost major component expense consist personnel cost include salary benefit clinical study perform contract research organization material supply overhead allocation consist administrative facility relate cost research development activity separate main category research clinical development pharmaceutical development research cost typically consist preclinical toxicology work clinical development cost include phase iii clinical trial expand access program pharmaceutical development cost consist product formulation chemical analysis record accrual estimate clinical preclinical study cost cost significant component research development expense management accrue cost clinical study perform contract research organization base estimate work upfront cost remain activity generally straightline basis life individual contract study estimate match actual service perform organization determine patient enrollment level relate activity monitor patient enrollment level relate activity extent possible management underestimate activity level associate study give point time record significant research development expense future period advertising expense company expense cost advertising include promotional expense incur advertising expense million million million stockbase compensation accordance provision sfas accounting stockbase compensation company elect follow accounting principle board opinion apb accounting stock issue employee interpretation fin account certain transaction involve stock compensationan interpretation apb opinion accounting employee stock option plan apb exercise price company employee director stock option equal exceed fair value underlie stock date grant compensation expense recognize note pro forma disclosure stockbase compensation pursuant sfas share computation basic net income common share compute base weighted average number common share outstanding period dilute net income common share include effect approximately million stock option warrant include effect million convertible note convert approximately million share effect antidilutive period present prior basic diluted loss common share compute base weighted average number common share outstanding period convertible note stock option warrant convertible debenture previously outstanding exclude computation dilute loss share effect antidilutive period present prior share share amount period present restate reflect stock split february march cash cash equivalent company consider highly liquid investment insignificant interest rate risk remain maturity month purchase date cash equivalent gilead enter overnight repurchase agreement purchase security obligation resell follow day security purchase agreement resell record face value report cash cash equivalent company investment policy enter repurchase agreement repos major bank authorize dealer provide repos collateralize government security fair value fair value security sell gilead marketable security management determine appropriate classification marketable security time purchase reevaluate designation balance sheet date company marketable security classify availableforsale carry estimate fair value report cash equivalent marketable security december cash cash equivalent include million security designate availableforsale million december unrealize gain loss availableforsale security exclude earning report separate component stockholder equity interest income include interest dividend amortization purchase premium discount realize gain loss sale security cost security sell base specific identification method regularly review investment otherthantemporary decline fair value determine decline fair value investment accounting basis otherthantemporary reduce carry value security hold record loss decline reduction require past year concentration credit risk gilead subject credit risk portfolio cash equivalent marketable security policy company limit amount invest security maturity industry group investment type issuer security issue government gilead expose significant concentration credit risk financial instrument hold share osi common stock result sale oncology asset osi seenote share fair value million december represent entire portfolio marketable equity security goal company investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return gilead subject credit risk account receivable relate product sale majority company trade account receivable arise sale ambisome primarily sale european subsidiary export sale distributor europe certain country payment typically slow primarily greece spain portugal italy account receivable balance significant case slow payment practice reflect pace governmental entity reimburse customer turn increase financial risk relate certain customer sale customer country tend relatively slow pay past increase future increase average length time account receivable outstanding date experience modest loss respect collection account receivable believe past account receivable include customer country collectible continually seek improve collection process ensure fully collect amount base product sale collection timely perform credit evaluation customer financial condition generally require collateral date experience modest credit loss respect account receivable inventory inventory record low cost market cost determine firstin firstout basis management periodically review composition inventory order identify obsolete slowmoving unsaleable item item observe alternate use inventory company record writedown net realizable value period unit identify impair historically inventory writedown insignificant consistent management expectation property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straight line method estimate useful life follow description estimate useful life year build leasehold improvement laboratory manufacturing equipment office computer equipment office computer equipment include capitalize computer software company capitalize software purchase company internally develop computer software leasehold improvement capitalize lease equipment amortize short lease term item useful life noncurrent asset noncurrent asset december include million prepay royalty pay institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega discuss iocbrega caption note include noncurrent asset december defer debt issuance cost million net accumulate amortization million relate million subordinate convertible note gilead issue december longlive asset carry value longlive asset review regular basis existence fact circumstance internally externally suggest impairment specific potential indicator impairment include significant decrease fair value asset significant change extent manner asset significant physical change asset significant adverse change legal factor business climate affect value asset adverse action assessment food drug administration regulator accumulation cost significantly excess originally expect acquire construct asset operate cash flow loss combine history operate cash flow loss projection forecast demonstrate continue loss associate incomeproduce asset indication impairment company confirm compare estimate future cash flow expect result use asset eventual disposition carry asset estimate future cash flow asset group low level identifiable cash flow largely independent cash flow generate asset group sum expect future cash flow undiscounte interest change carrying asset impairment loss measure excess carrying value asset fair value recognize cash flow estimate calculation base management good estimate appropriate customary assumption projection time current accrue liability december december accrue liability include million accrue litigation settlement cost legal proceeding discussion note foreign currency translation transaction contract adjustment result translate financial statement company foreign subsidiary dollar exclude determination net income accumulate separate component stockholder equity net foreign exchange transaction loss report sell general administrative expense consolidated statement operation loss million million million company hedge certain foreign currency exposure related outstanding trade account receivable firmly commit purchase transaction foreign exchange forward contract general contract expose company market risk gain loss contract offset gain loss transaction hedge company exposure credit risk contract function change interest currency exchange rate vary time gilead limit risk counterpartie contract unable perform transact major bank company limit risk loss enter contract provide net settlement maturity company overall risk loss event counterparty default limit unrecognize unrealized gain outstanding contract contract positive fair value date default company enter speculative foreign currency transaction write option accounting hedge account receivable company aggregate net foreign currency transaction gain loss report sell general administrative expense prior adoption sfas january company recognize net unrealized gain loss outstanding forward contract base difference contract exchange rate market exchange rate balance sheet date respect hedge firmly commit purchase transaction unrealize gain loss underlie forward contract defer report component relate transaction period occur december company net unrealize loss open foreign exchange forward contract million company forward exchange contract outstanding million december million december contract maturity year exception hedge contract intend hedge raw material purchase quarter notional million fair value december maturity month company presently hedge net investment foreign subsidiary effective january begin use forward contract hedge percentage forecast international sale primarily denominate euro currency note discussion derivative financial instrument adoption sfas fair value financial instrument company financial instrument consist principally cash cash equivalent marketable security account receivable certain noncurrent asset forward foreign exchange contract account payable longterm obligation convertible subordinate note cash cash equivalent marketable security forward foreign exchange contract hedge account receivable report respective fair value balance sheet forward foreign exchange contract hedge firmly commit purchase record fair value net relate deferred gain loss result report net balance zero management believe remain financial instrument exception convertible subordinate note report balance sheet amount approximate current fair value fair value convertible subordinate note december million fair value december million carrying value end period million fair value december determine obtain quote market maker note fair value december obtain multiply number share note convert share market price gilead common stock december plus accrue interest recent accounting pronouncement july financial accounting standard board fasb issue sfas business combination sfas goodwill intangible asset sfas sfas eliminate poolingofinterest method accounting business combination qualify business combination initiate prior july sfas clarifie criterion recognize intangible asset separately goodwill requirement sfas effective business combination account purchase method complete june sfas goodwill indefinite live intangible asset long amortize review annually frequently impairment indicator arise impairment separable intangible asset deem indefinite life continue amortize useful life maximum life amortization provision sfas apply goodwill intangible asset acquire june gilead account business combination purchase method accounting adoption sfas july material impact company financial position result operation adoption sfas january material impact company financial position result operation august fasb issue sfas accounting impairment disposal longlive asset sfas establish single accounting model asset dispose sale previously hold newly acquire sfas retain presentation discontinue operation income statement broaden presentation include component entity sfas effective fiscal year begin december interim period adoption sfas january material impact company financial position result operation cumulative change accounting principle december securities exchange commission issue staff accounting bulletin sab revenue recognition financial statement thing sab describe sec staff position recognition certain nonrefundable upfront fee receive connection collaboration agreement company previously recognize nonrefundable technology access fee receive connection collaboration agreement revenue receive collectibility probable technology transfer effective january gilead change method accounting fee recognize related manufacturing obligation fulfil straightline basis term relate research development collaboration manufacturing supply arrangement appropriate method good match effort provide management believe change accounting principle preferable base guidance provide sab cumulative effect change accounting principle record fourth quarter retroactively effective january defer revenue recognize contract revenue remain term research development manufacturing supply arrangement appropriate year end december net impact change accounting principle increase net loss million share loss consist million cumulative effect change ofjanuary net million relate defer revenue recognize contract revenue year additional million contract revenue recognize remainder million relate deferred revenue balance december expect recognize revenue fiscal year derivative financial instrument january gilead adopt sfas standard require gilead recognize derivative asset liability measure fair value derivative designate meet definition fair value hedge change fair value derivative hedge item attributable hedge risk recognize earning derivative designate meet definition cash flow hedge effective portion change fair value derivative record comprehensive income recognize income statement hedge item affect earning ineffective portion change fair value cash flow hedge recognize earning immediately sfas classify warrant purchase capital stock nonpublic company include net exercise feature derivative adoption record balance sheet fair value offset record result operation subsequent change fair value warrant require remeasure balance sheet date change fair value warrant record result operation gilead sell product purchase raw material internationally dollar local currency forecast actual foreign currency risk hedge forward currency contract generally maturitie month derivative instrument employ eliminate minimize certain foreign currency exposure confidently identify quantify forward contract hedge nonfunctional currency asset liability sfas designate hedge change fair value recognize immediately earning accordance sfas hedge relate anticipate foreign currency purchase raw material designate document inception respective hedge designate cash flow hedge evaluate effectiveness quarterly term forward contract underlie transaction match inception forward contract effectiveness calculate compare fair value contract change forward value underlie hedged item effective portion gain loss derivative instrument report component comprehensive income stockholder equity reclassify earning period period hedge transaction affect earning adoption sfas record fair value million relate forward contract previously reflect balance sheet recognize cumulative transition adjustment comprehensive income million effective component hedge substantially value report comprehensive income december reclassify earning month residual change fair value instrument ineffectiveness recognize immediately sell general administrative expense ineffectiveness significant gilead hold warrant purchase stock nonpublic company warrant net exercise feature sfas classify derivative instrument adoption gilead record fair value warrant offset adjustment cumulative change accounting principle year end million loss hedge contract recognize income statement million reduction fair value derivative recognize comprehensive income december fair value derivative recognize comprehensive income material sale oncology asset december gilead complete sale oncology asset pipeline clinical candidate oncology relate intellectual property boulder colorado operation include clinical research drug development operation infrastructure facility osi pharmaceuticals inc osi clinical development candidate sell osi liposomal lurtotecan nucleoside analogue liposomal thymidylate synthase inhibitor consideration gilead receive million cash share osi common stock value approximately million december number share issue gilead determine divide million average closing sale price osi common stock day precede december entitle additional payment osi million cash combination cash osi common stock osi reach certain development milestone advanced oncology product candidate sell osi base december net book value oncology asset sell million transaction cost million million relate acceleration approximately option purchase gilead common stock company realize pretax gain million fourth quarter carry value transfer asset relate primarily certain property equipment osi assume gilead oncologyrelate clinical preclinical obligation lease obligation relate manufacturing agreement produce osi liposomal formulation liposomal product sell osi manufacturing facility san dimas acquisition nexstar july company acquire outstanding common stock nexstar pharmaceutical agreement date february result nexstar wholly own subsidiary gilead connection merger gilead issue total million share gilead common stock nexstar stockholder consideration share common stock nexstar addition holder option warrant outstanding time merger purchase aggregate approximately million share nexstar common stock receive exercise option warrant fraction share gilead common stock holder million principal convertible subordinate debenture nexstar receive right convert debenture approximately million share gilead common stock merger qualified taxfree reorganization account pool interest table present separate result operation gilead nexstar period prior merger combine result merger thousand mergerrelate gilead nexstar adjustment total year end december revenue net income loss mergerrelate costsb adjustment require conform accounting policy nexstar policy capitalize certain patent trademark cost gilead policy charge item sell general administrative expense period incur accompany financial statement restate period patent trademark cost expense incur result merger nexstar company incur mergerrelate cost consist transaction cost primarily professional fee filing fee print cost relate charge employee severance cost writedown certain nexstar asset continue operation follow table show detail mergerrelate cost accrual december thousands charge expense december december utilize accrual balance merger transaction cost employee severance writedown nexstar asset total employee severance cost accrue terminate december substantially remain accrue severance cost pay employee december merger transaction cost utilize december availableforsale security follow summary availableforsale security estimate fair value availableforsale security base price obtain commercial pricing service thousand gross gross amortize unrealize unrealized estimate cost gain loss fair value december treasury security obligation government agency certificate deposit corporate debt security corporate equity security assetbacke security debt security total december treasury security obligation government agency certificate deposit corporate debt security assetbacke security debt security total debt security consist primarily money market fund follow table present certain information relate sale availableforsale security thousand year end december proceed sale gross realize gain sale gross realize loss sale december million company portfolio marketable security exclude million assetbacke security million equity security contractual maturity year million portfolio contractual maturity great year year estimate maturity company assetbacked security exceed year marketable equity security consist osi common stock expect available sale half collaborative arrangement contractscubist pharmaceutical january gilead enter agreement cubist pharmaceuticals inc cubist relate cubist antibacterial compound daptomycin include cidecin intravenous formulation compound currently phase iii clinical trial treatment bacterial infection term agreement gilead pay cubist upfront license fee million receive exclusive commercial right compound sixteen european country gilead territory right develop compound commercialization territory research development expense charge million million payment million balance include noncurrent asset december prior january gilead terminate right agreement respect preclinical oral formulation daptomycin develop cubist cubist discontinue development oral formulation gilead entitle receive refund cubist subsequent january refundable reduce ratably monthly basis fouryear period amortize research development expense cubist continue responsible worldwide clinical development cidecin preclinical oral formulation gilead responsible regulatory filing marketing selling product gilead territory gilead agree additional payment cubist million certain clinical regulatory milestone relate cidecin oral formulation reach milestone meet gilead pay million relate milestone payment record research development expense additionally cidecin successfully commercialize gilead territory gilead pay cubist royalty net sale product archemix october enter agreement archemix corporation relate selex technology agreement give archemix exclusive right selex process include therapeutic commercial application extent license preexist agreement archemix pay million require pay million require license agreement university technology corporation pay million payment pay million payment university technology corporation receive warrant purchase share archemix common stock value material require license agreement university technology corporation transfer warrant university technology corporation eyetech march gilead enter agreement eyetech pharmaceuticals inc relate gilead proprietary aptamer eye currently early clinical trial eye inhibitor vascular endothelial growth factor vegf know play role development certain ophthalmic disease term agreement eyetech receive worldwide right therapeutic use eye product successfully commercialize eyetech pay gilead royalty worldwide sale product eyetech responsible research development cost gilead provide clinical supply product eyetech march gilead receive million upfront licensing fee eyetech april recognize revenue ratably oneyear supply agreement period accordingly million license fee record contract revenue agreement remainder license fee recognize revenue gilead entitle additional cash payment eyetech million eyetech reach certain eye development milestone additionally gilead receive warrant purchase share eyetech series convertible prefer stock exercisable price share price stock issue investor note description account treatment warrant fujisawa company right market ambisome subject agreement company fujisawa healthcare inc successor fujisawa usa inc fujisawa term fujisawa agreement amend fujisawa company copromote ambisome united states fujisawa sole marketing right ambisome canada company exclusive marketing right ambisome rest world provide company pay royalties fujisawa connection sale significant asian market include japan connection sales fujisawa purchase ambisome company cost sale canada fujisawa purchase ambisome cost plus specify percentage fujisawa collect payment sale ambisome united states canada company receive fujisawa gross profit sale ambisome united states gross profit include deduction cost good sell give company current effective royalty rate approximately fujisawa net sale ambisome united states connection agreement company fujisawa gilead record royalty revenue million million million sumitomo september company sumitomo pharmaceutical ltd sumitomo enter agreement sumitomo license pursuant sumitomo agree develop market ambisome japan term sumitomo license sumitomo pay company initial million licensing fee withholding taxis million october million milestone payment withholding taxis million march sumitomo require additional payment company certain clinical commercial milestone meet pay company royalty japanese ambisome sale sumitomo license gilead obligate provide certain quantity ambisome sumitomo charge ambisome approve marketing japan subsequent cumulative effect change accounting principle record effective quarter result adoption sab gilead recognize initial license fee remain free supply arrangement period currently expect year net impact change accounting principle sumitomo license increase net loss million cumulative effect change accounting principle charge million contract revenue million relate initial licensing fee sumitomo recognize contract revenue million recognize contract revenue remain million relate defer revenue december recognize contract revenue remain free supply obligation period hoffmannla roche september gilead enter collaboration agreement hoffmannla roche ltd hoffmannla roche inc collectively roche develop commercialize therapy treat prevent viral influenza roche agreement roche agreement roche receive exclusive worldwide right togilead proprietary influenza neuraminidase inhibitor prior roche license fee developmental milestone payment total million gilead recognize total million additional milestone payment commencement certain clinical trial japan filing application market tamiflu european union file subsequent approval market tamiflu united states gilead recognize million contract revenue milestone payment roche relate tamiflu milestone achieve year milestone include file regulatory approval japan treatment influenza japanese approval application file regulatory approval prevention influenza receipt approval recognize million milestone payment filing application market tamiflu prophylaxis european union subsequent cumulative effect change accounting principle record effective quarter result adoption sab gilead recognize initial license fee remain research development period end quarter net impact change account initial license fee zero cumulative effect change accounting principle relate roche license fee million charge result operation offset additional contract revenue million recognize quarter remain defer revenue relate roche initial license fee december december gilead entitle additional cash payment roche million roche achieve additional developmental regulatory milestone addition roche require pay gilead royalty net product sale gilead begin receive royalty roche sale tamiflu quarter record total million tamiflu royalty year million royalty tamiflu royalty record company recognize royalty revenue roche quarter follow quarter relate tamiflu sale occur roche agreement roche reimburse company relate cost program funding cost quarterly generally advance base annual budget reimbursement include contract revenue company incur relate cost amount incur company excess amount fund reimburse subject roche approval event revenue recognize approval obtain conversely amount fund roche exceed company relate cost company require repay excess funding roche company record contract revenue reimbursement relate roche agreement approximately million million million cost relate roche agreement approximate reimbursement revenue year present include expense pharmacia august company pharmacia corporation pharmacia enter license supply agreement pharmacia agreement market vistide country outside united states term pharmacia agreement pharmacia pay gilead initial license fee million subsequent cumulative effect change accounting principle record effective quarter gilead recognize initial license fee straightline basis supply arrangement period sixteen year agreement date net impact change accounting principle pharmacia agreement increase net loss million cumulative effect change accounting principle relate initial license fee pharmacia million charge result operation additional contract revenue million recognize subsequent accounting change remain million relate deferred revenue expect recognize straightline basis contract revenue remain supply period year begin january second quarter vistide approve marketing european union european commission trigger additional cash milestone payment million pharmacia company result achieve milestone second quarter pharmacia purchase shares series convertible prefer stock approximately million share prefer stock automatically convert share common stock additional information prefer stock note term pharmacia agreement relate agreement cover expand access program vistide outside united states gilead responsible maintain cidofovir patent portfolio supply pharmacia bulk cidofovir manufacture finish vistide product gilead entitle receive royalty base pharmacia sale vistide gilead receive portion royalty ship bulk drug substance vistide pharmacia remainder pharmacia sale vistide party royalty gilead receive product sell party record defer revenue thirdparty sale occur december company record balance sheet approximately million defer revenue million december company recognize royalty revenue sale vistide outside united states pharmacia million million million somalogic november gilead somalogic inc somalogic enter agreement gilead assign somalogic sole exclusive license certain intellectual property relate selex process diagnostic purpose include patent patent application term agreement somalogic require pay gilead total million nonrefundable installment million pay november include contract revenue year end december remain million report defer revenue december receive record contract revenue gilead ongoing research funding obligation agreement schering company enter collaborative research agreement schering research agreement license agreement schering license agreement schering schering research agreement schering fund research gilead discovery development aptamer vivo diagnostic agent level funding agreement vary annually high million million receive record contract revenue schering research agreement expire company expect receive additional payment thereunder schere license agreement schering right develop commercialize aptamer vivo diagnostic agent radiotherapeutic discover develop schering research agreement schering require milestone royalty payment company commercialization sale product develop collaboration company milestone payment product total million trigger file investigational new drug application initiation phase iii clinical trial file nda approval product commercial sale schering license agreement effect december permit company develop commercialize aptamer discover schering research agreement outside field vivo diagnostic agent radiotherapeutic subject royalty payment schere agglaxosmithkline december gilead enter agreement glaxo wellcome glaxosmithkline glaxo give gilead right novel antitumor compound gilead develop liposome evaluate preclinical study agreement gilead exclusive worldwide right develop commercialize indication malaria gilead pay glaxo upfront fee include expense december compound assign osi sale oncology asset gilead enter threepart collaboration glaxo glaxo receive nonexclusive right use gilead proprietary selex process target validation gilead receive exclusive right subject glaxo right elect participate activity develop commercialize liposomal formulation glaxo proprietary topoisomerase inhibitor lurtotecan glaxo acquire share gilead common stock million private offering december collaboration license agreement modify revise term agreement glaxo waive right participate development commercialization right receive royalty give gilead exclusive right compound december compound assign osi sale oncology asset iocbrega gilead enter agreement institute organic chemistry biochemistry academy sciences czech republic rega stichte iocbrega relate certain nucleotide compound discover institution agreement gilead receive exclusive right manufacture use sell nucleotide compound gilead obligate pay iocbrega percentage net revenue receive sale product contain compound subject minimum royalty payment product cover agreement include vistide adefovir dipivoxil viread exclude tamiflu gilead currently make quarterly payment iocbrega base percentage vistide viread sale marketing approval receive fda adefovir dipivoxil gilead obligate pay additional amount iocbrega future sale product december agreement iocbrega amend provide reduce royalty rate future sale adefovir dipivoxil viread return upfront payment gilead million signing agreement payment record longterm prepay royalty classified noncurrent asset balance sheet december recognize royalty expense expect commercial life viread recognize royalty expense expect commercial life adefovir dipivoxil fda approval obtain sale product commence amortization million payment significant december southern research institute december gilead enter agreement southern research institute give gilead worldwide right develop commercialize antitumor compound gilead evaluate preclinical study term agreement gilead pay southern research institute upfront fee include research development expense december compound assign osi sale oncology asset inventory inventory summarize follow thousand december raw material work process finish good property plant equipment property plant equipment consist follow thousand december building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment capitalize lease equipment construction progress accumulate depreciation amortization investment sale unconsolidate affiliatein july company establish proligo llc delaware limited liability company proligo wholly own subsidiary transfer asset nexstar technology product division proligo proligo supply nucleic acid peptide synthesis product pharmaceutical biopharmaceutical industry sale use laboratory research reagent therapeutic diagnostic product august company sell interest interest proligo skw americas inc skw payment interest company receive million cash interest perseptive biosystem gmbh company hamburg germany hamburg company specialize manufacture nucleoside phosphoramidite monomer interest hamburg company fair market value approximately million addition skw agree pay company million guarantee payment discount gain recognition purpose million performancebase milestone year gilead receive million guarantee payment skw past year gilead receive performance base milestone payment million include contract revenue original transaction company contribute million interest hamburg company proligo company record million gain connection sale skw contribute million remain interest hamburg company proligo connection transaction company proligo agree proligo manufacture oligonucleotide require company cost plus fixed percentage company purchase oligonucleotide proligo total million purchase purchase charge expense january october gilead additional cash investment proligo total million maintain ownership interest proligo gilead commitment provide additional funding proligo january company account investment proligo equity method accounting net book value investment million december report noncurrent asset company consolidated balance sheet gilead record million equity loss proligo prior date sale recognize million equity proligo net loss represent share proligo loss thirteenmonth period end december fourth quarter proligo change fiscal year end december november gilead record million equity loss proligo proligo fiscal year end november gilead sell interest proligo degussa corporation million cash proceed net gilead investment proligo reflect million gain sale unconsolidated affiliate longterm obligation longterm obligation consist follow thousand december capital lease obligation monthly installment interest rate range fix rate debt monthly installment secure equipment interest rate range total longterm obligation current portion longterm obligation year maturitie longterm obligation include capital lease obligation follow thousand year represent interest total term debt agreement require company comply certain financial operating covenant december company compliance covenant convertible subordinate note debenture december gilead issue million convertible subordinated note december private offering morgan lehman brothers morgan stanley dean whitter resold note private institutional investor note convertible total share gilead common stock share conversion price high gilead common stock price note issue date note redeemable option company time december specify redemption price plus accrued interest debt issuance cost million incur connection issuance note record noncurrent asset amortize interest expense straightline basis contractual term note quarter gilead issue million convertible subordinated debenture private offering sbc warburg inc oppenheimer inc resold debenture group private investor debenture issue pursuant indenture convertible total share gilead common stock share debenture redeemable option company time august specify redemption price plus accrued interest gilead call debenture redemption august cash price principal debenture outstanding plus accrued interest redemption price provide original debenture indenture entire million principal debenture outstanding time convert newly issue share gilead common stock prior august defer debt issuance cost million relate debenture charge additional pay capital connection conversion debenture common stock commitment contingency lease arrangement company enter longterm noncancelable operating lease facility foster city san dimas california lease expire date lease fiveyear renewal option exception lease foster city expire contain renewal option company operating lease sale marketing administrative facility europe australia term miscellaneous equipment lease rent expense net sublease income company operating lease total approximately million million million company enter capital lease finance equipment purchase facility improvement title asset acquire lease line credit reside lessor company option purchase asset end lease term fair market value lease remain term year december additional amount available agreement aggregate noncancelable future minimum rental payment operate capital lease net aggregate future minimum rental receive company noncancelable sublease follow thousand operating lease net year end december noncancelable sublease capital lease represent interest total capital lease obligation current portion capital lease obligation year december company place million bank escrow deposit secure aggregate future payment facility lease contingent liability gilead sublease certain facility primarily california sublessee default obligation sublease company primarily liable original lessor total lease december million line credit april maintain million unsecured line credit bear interest float rate major financial institution term line credit require maintain certain financial ratio limitation ability incur additional debt engage certain significant transaction line credit include foreign exchange facility expire april renew foreign exchange facility renew line credit require financial ratio limitation debt transaction foreign exchange facility legal proceeding august company elan corporation plc elan successor company liposome company inc reach settlement settlement agreement company agree dismiss legal proceeding involve ambisome gilead liposomal formulation amphotericin settlement agreement elan grant company immunity suit connection worldwide production sale ambisome worldwide right use patent term settlement agreement gilead initial payment elan million require payment begin intheir patent term settlement agreement gilead initial payment elan million require payment beginning base ambisome sale year payment subject certain minimum maximum amount company record accounting charge million million represent net present value future minimum payment million represent initial cash payment begin gilead record expense quarter base difference future minimum payment expense record addition begin company recognize cost good sell difference minimum maximum payment gilead expect difference future minimum maximum payment elan material company involve time time legal proceeding arise ordinary course business opinion management matter expect material adverse effect financial position operation company base factor currently know management stockholder equity stock split february march gilead complete twoforone stock split effect form stock dividend stockholder record february february respectively accordingly share share amount period present restate reflect split preferred stock company share authorize preferred stock issuable series company board director board authorize determine designation power preference right series company reserve share prefer stock potential issuance preferred share purchase right plan june company issue shares series convertible prefer stock prefer stock pharmacia approximately million share july average closing price gilead common stock thirty day end event trigger automatic conversion prefer stock own pharmacia company common stock accordingly prefer stock convert share common stock price share july preferred stock outstanding december employee stock purchase plan gilead employee stock purchase plan espp employee purchase share gilead common stock base percentage compensation purchase price share equal low percent market value date offer date purchase total share common stock reserve issuance espp december share total share reserve issue espp share december stock option plan december gilead adopt incentive stock option plan supplemental stock option plan issuance common stock employee consultant scientific advisor april board approve grant certain additional nonqualified stock option term condition substantially similar grant supplemental stock option plan option describe exercise price fair value underlie stock date grant option vest year pursuant formula determine board expire year share available grant future option plan november gilead adopt stock option plan plan issuance common stock employee consultant option issue plan shall discretion board incentive stock option nonqualifie stock option plan amend exercise price stock option equal fair value gilead common stock date grant option vest year pursuant formula determine board expire year stockholder approve amendment plan increase total number authorize share plan december share available grant future option plan november gilead adopt nonemployee director stock option plan director plan issuance common stock nonemployee directors pursuant predetermine formula exercise price option grant director plan equal fair value gilead common stock date grant option vest year date grant quarterly percent installment expire year december share available grant future option director plan stock plan assume gilead merger nexstar include stock option plan plan incentive stock plan director option plan collectively nexstar plan option pursuant stock option plan incentive stock plan issue outstanding july convert option purchase gilead common stock result merger remain subject original term condition share available grant future option nexstar plan nexstar plan allow certain option holder execute cashless exercise option cashless exercise transaction option holder specify share exercise company issue specify number share number require cover exercise price base fair value stock exercise date option holder perform cashless exercise result option award consider variable company recognize compensation expense million million million million relate exercise option remain million relate option remain outstanding plan december follow table summarize activity gilead nexstar stock option plan year period end december option grant present table exercise price fair value underlie stock grant date share thousandsyear end december weight weight weight average average average exercise exercise exercise share price share price share price outstanding beginning year grant forfeit exercise outstanding end year exercisable end year weight average fair value option grant follow summary gilead option outstanding option exercisable december option thousand option outstanding option exercisable weighted average weight remain average weighted option contractual exercise option average range exercise price outstanding life year price exercisable exercise price total stockholder equity pro forma disclosure table present combine net income loss basic diluted net income loss common share compensation cost gilead nexstar stock option plan espp determine base estimate fair value award plan grant purchase date year end december pro forma net income loss thousand pro forma net income loss common sharebasic pro forma net income loss common sharedilute fair value award grant stock option plan espp estimate grant purchase date blackschole option pricing model company multiple option approach follow assumption year end december expect life year vest date stock option espp discount rate stock option espp volatility expect dividend yield weight average estimate fair value espp share purchase preferred share purchase right plan november company adopt preferred share purchase right plan plan provide distribution prefer stock purchase right dividend share gilead common stock purchase right currently exercisable certain condition involve acquisition propose acquisition person group company common stock purchase right permit holder holder purchase gilead common stock discount market price time payment specify exercise price purchase right addition event certain business combination purchase right permit purchase common stock acquirer discount market price time certain condition purchase right redeemed board price purchase right purchase rightshave voting privilege attach automatically trade gilead common stock october board director approve amendment purchase right plan amendment provide thing increase exercise price right plan extension term plan november october acceleration stock option december complete sale oncology asset osi transaction accelerate approximately option purchase gilead common stock value million note discussion comprehensive income loss follow reclassification adjustment require avoid doublecounte net realize gain loss sale security previously include comprehensive income prior sale security thousand year end december net gain loss sale security include interest income comprehensive income net unrealize gain loss arise year reclassification adjustment net unrealized gain loss report comprehensive income balance accumulate comprehensive income loss report balance sheet consist follow component thousand december net unrealized gain availableforsale security net unrealize gain cash flow hedge net foreign currency translation loss accumulate comprehensive income loss disclosure segment enterprise related information company determine reportable segment management organize business functional line product sale consist follow thousands year end december ambisome viread follow table summarize revenue external customer collaborative partner geographic region revenue attribute country base location customer collaborative partner thousand year end december united states united kingdom germany italy spain france switzerland european country country consolidate total revenue december net book value company property plant equipment million approximately asset locate united states december net book value property plant equipment million approximately asset locate united states product sale distributor exceed total revenue product sale distributor account approximately total revenue total revenues fujisawa healthcare inc include product sale royalty approximately total revenue revenue roche include royalty milestone payment reimbursement research development expense exceed total revenue account approximately total revenue income taxis company defer provision income taxis current provision income taxis consist follow thousands year end december current provision federal state foreign foreign pretax income loss million million million difference provision taxis income compute apply federal statutory income tax rate income provision income taxis equity loss unconsolidated affiliate cumulative effect change accounting principle explain thousands year end december income loss provision income taxis equity loss unconsolidated affiliate cumulative effect change accounting principle tax federal statutory rate benefit unbenefitted loss federal alternative minimum taxis december company federal net operating loss carryforward million state net operating loss carryforward million federal net operating loss carryforward expire date begin utilize state net operating loss carryforward expire date utilize addition company federal state tax credit carryforward approximately million million respectively expire year utilization net operating loss credit subject annual limitation ownership change limitation provide internal revenue code similar state provision annual limitation result expiration net operating loss credit utilization income taxis continue deferred income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component company defer tax asset liability december follow thousand december net operating loss carryforward research credit capitalize california net total defer tax asset valuation allowance net defer tax asset recognize valuation allowance decrease million year end december increase million year end december approximately million valuation allowance december relate tax benefit stock option deduction credit additional paidin capital realize retirement saving plan december company maintain retirement saving plan eligible employee defer compensation income tax purpose section internal revenue code prior january gilead maintain separate retirement saving plan plan primarily cover nexstar employee nexstar plan plan primarily cover gilead remain eligible employee gilead plan nexstar plan employee contribution exceed eligible annual compensation addition nexstar plan include company match employee contribution maximum contribution annual maximum company match december approximately million represent share gilead common stock hold nexstar plan trust plan participant effective january nexstar plan terminate combined gilead plan share gilead common stock hold nexstar plan subsequently liquidate proceed deposit investment option available gilead plan gilead plan employee contribute eligible annual compensation effective january gilead begin make match contribution gilead plan company contribute employee contribution annual maximum company match company total matching contribution gilead plan million combine million plan million nexstar plan relate party transaction december chairman gilead board director senior advisor investment fund own control interest pharmaresearch corporation contract research organization perform service connection clinical study gilead payment pharmaresearch corporation million million quarterly result unaudite follow table thousand share amount quarter quarter quarter quarter total revenue total cost expense income loss cumulative effect change accounting principle cumulative effect change accounting principle net loss amount common sharebasic income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharebasic amount common sharedilute income loss cumulative effect change accounting principle cumulative effect change accounting principle net income loss sharedilute quarter quarter quarter quarter total revenue total cost expense loss cumulative effect change accounting principle cumulative effect change accounting principle net loss basic diluted amount share loss cumulative effect change accounting principle cumulative effect change accounting principle net loss year end december gilead adopt sfas report cumulative effect change accounting principle quarter year end december adopt sab report cumulative effect change accounting principle accounting change adopt fourth quarter effective quarter quarter restate retroactively reflect change february march gilead complete twoforone stock split effect form stock dividend stockholder record february february respectively accordingly share share amount period present restate reflect split dilute net income common share fourth quarter include effect stock option million convertible subordinate note december complete sale oncology asset osi company record nonoperate gain million fourth quarter result transaction gilead sciences inc schedule valuation qualifying account addition balance balance begin charge charge end period expense deduction period year end december allowance doubtful account valuation allowance defer tax asset year end december allowance doubtful account valuation allowance defer tax asset year end december allowance doubtful account valuation allowance defer tax asset charge current tax expense charge defer tax benefit